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ABSTRACT

EFFECTS OF STZ INDUCED HYPERGLYCEMIA AND
HYPERLIPEMIA ON PPARy
AND ABCA1 IN A HAMSTER MODEL OF ATHEROGENESIS

By
Craig J. LaMarca
University of New Hampshire, September 2006

Diabetes mellitus accelerates atherogenesis, but the exact mechanisms
involved are unknown. This study examined the effects of hyperglycemia on the
inflammatory transcription factor peroxisome proliferator activated receptor gamma
(PPARy), known to be involved in atherogenesis, and the ATP binding cassette A1
(ABCA1) protein that is a downstream product of PPARy. ABCA1 is a membrane
bound transporter that is involved in reverse cholesterol transport via high density
lipoprotein cholesterol (HDL-C). Hamsters were divided into two groups;
hyperlipemic animals fed a high fat/high cholesterol control diet (C) and
hyperlipemic/hyperglycemic animals that received the high fat diet and were
administered streptozotocin. Half of the hamsters (23) in each group were sacrificed
at 8 weeks and the other half at 24 weeks. To determine the role of PPARy and
ABCA1 in atherogenesis, aortas were harvested for ELISA, western blot and
immunohistochemical analyses of PPARy and ABCA1. The 8 week hyperlipemic
hamsters had lower total cholesterol levels than the 8 week treated hamsters and both
groups at 24 weeks. At 8 and 24 weeks, the TG levels of the treated hamsters’ were
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elevated over controls, 24 week control values were higher than 8 week controls, but
24 week treated values were lower than at 8 weeks (p<.05). Hemoglobin A1C
(HbAlC) levels were higher (p<.001) in both treatment groups as compared to the
controls but there were no differences between time points. HDL-C levels were lower
in the 24 week treatment hamsters compared to all other groups. Non-HDL
cholesterol values were higher (p<.05) in treatment groups at both time points and 24
week controls were higher than 8 week controls. TC/HDL ratios were higher (p<.05)
in both treatment groups as compared to controls and were higher (p<.05) in both
groups at 24 weeks as compared to 8 weeks. Advanced fatty streak lesions were
observed in the 8 week treatment group and in both the control and treatment
hamsters at 24 weeks. The most advanced lesions were observed in the 24 week
treatment animals. Both 8 week control and treated aortas as well as 24 week controls
had mild focal reactions for PPARy and ABCA1 based on IHC, and while the 24
week treatment sections had multi-focal, intense immunoreactivity. Thus, based on
the immunohistochemical and ELIAS analyses, the 24 week treated animals showed a
greater expression o f PPARy and ABCA1. Although activated PPARy was detected
by ELISA in all groups, there were no statistical differences between groups.
However, average 8 week treated values were higher than 8 week controls and 24
week controls were higher than both 8 week control and treated aortas. Treated values
at 24 weeks declined as compared to controls. Due to extremely low protein
concentrations, comparisons could not be made on western blot data although PPARy
was detectable. Hyperglycemia as compared to hyperlipemia produced a more
atherogenic lipid profile, more advanced arterial lesions, and observed increases in
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PPARy and ABCA1 expression. The added metabolic stress of hyperglycemia in
addition to hyperlipemia appeared to induce the further expression of PPARy and
ABCA1, although the potential beneficial effects of this were outweighed by the
extremely adverse lipid profile.
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CHAPTER 1
INTRODUCTION
According to the American Heart Association, cardiovascular disease (CVD) is
the leading cause of morbidity and mortality in the Western World [1]. In the United
States alone, over 71 million American adults are living with one or more types of CVD
and over 13 million of them have coronary heart disease (CHD) i.e., a coronary artery
narrowing leading to hypoxia, inadequate nutrient provision and decreased metabolite
removal [1]. CHD is also the leading cause of death in patients with type 2 diabetes, and
the relative risk for developing CHD in diabetic patients is increased 2-4 fold [2].
Preliminary mortality data show that CVD was the underlying cause of over 37% of all
deaths (2,444,000) in the United States in 2003, and over 58% of all deaths in 2002 [1].
The threat that CVD poses is certainly not a new one; CVD has been the number one
killer in the US every year since 1900 with the exception of 1918, claims the lives of
2500 Americans each day, and is responsible for one death every 35 seconds [1].
It is now well known that atherosclerotic coronary artery disease is a major
complication of diabetes mellitus, a disease that affects the lives of more than 14 million
Americans [3], One might assume that confounding variables might play a role in the
increased incidence o f CVD in diabetic patients, as a number of pre-defined risk factors
for CVD such as elevated blood pressure and abnormal lipid profiles are more common
in diabetics as compared to the general population. However, no more than 25% of the
excess atherosclerotic risk from diabetes can be attributed to these known risk factors [4].
But, there is statistical evidence that CVD accounts for up to 80% of the deaths in
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patients with type 2 diabetes mellitus. The connection has focused worldwide research on
the connection between type 2 diabetes and the increased incidence of CVD in these
individuals. Many mechanisms have been proposed as commonalties between these
disease states, but none as prevalent or convincing as inflammation. Overall,
hyperglycemia, the root cause of both type 1 and 2 diabetes mellitus, seems to exacerbate
the mechanisms that contribute to the development o f CVD. More specifically, platelet
hyperaggregability and or increased platelet adhesiveness and coagulation abnormalities,
in addition to hypertension, all contribute to the accelerated development of
atherosclerosis seen in type 2 diabetics [5]. On the cellular level, the hyperglycemia,
hyperinsulinemia, and proatherogenic dyslipidemia associated with diabetes all
contribute to complex vascular interactions that induce the atherogenic process. The
dyslipidemia often observed in diabetics is associated with elevated levels of small, dense
low density lipoprotein (LDL-C) particles, low levels of high density lipoprotein (HDLC) as well as elevated triglycerides (150 mg/dL or higher). Elevated levels of
triglycerides (hypertriglyceridemia), which is associated with increased circulating levels
o f triglyceride-rich lipoproteins, has been implicated as a risk factor for atherosclerosis
and progression of coronary artery disease [6]. Hypertriglyceridemia is one of the
metabolic abnormalities commonly observed in insulin resistant individuals. Diabetics
experience extensive metabolic abnormalities such as increased circulating levels of
inflammatory markers including C-reactive protein (CRP), TNF-a, as well as increased
expression of the pro-inflammatory adhesion molecules intercellular adhesion molecule
(ICAM) and vascular cell adhesion molecule (VCAM). The extent of biochemical
changes in diabetics is complex and not-yet fully understood. One widely studied aspect

2

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

of the biochemical abnormalities associated with insulin resistance and diabetes is the
irreversible formation of advanced glycation end products (AGEs) with arterial wall
proteins, lipids and nucleic acids. Increased circulating levels of AGEs and subsequent
activation of their receptors (RAGE) on endothelial cells increases oxidative stress and
activates protein kinase C, which eventually alters normal cellular function. The
activation o f the AGE-RAGE cascade induces the expression of adhesive molecules such
as VCAM resulting in localization of circulating inflammatory cells to disease prone
segments of the vasculature. This type of low-grade inflammation is a hallmark of
diabetes which includes increasing circulating levels of inflammatory markers including
CRP, fibrinogen, pro-inflammatory cytokines (TNF- a), adhesion molecules (ICAM and
VCAM), IL-6 and a host o f other inflammatory markers [7], Hence, the association of
inflammation with both the development of type 2 diabetes and atherosclerosis suggests a
possible connection where by diabetes mellitus may accelerate the progression of
atherosclerosis. This study will examine the effects of hyperglycemia on mediators of
inflammation and dyslipidemia elucidating possible connections between the two disease
states.

Diabetes Mellitus
About 21 million people, or 7 percent of the United States population, are
currently living with some form of diabetes mellitus, and another 6 million people are
estimated to be living unknowingly with the disease [8]. Type I diabetes mellitus, also
referred to as insulin dependent diabetes, affects approximately 10% of all diagnosed
cases, and is characterized by immunologic destruction o f the insulin producing (3-cells in
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the pancreas [9]. Type I diabetes most often occurs early in life (aka: juvenile diabetes)
and is characterized by two distinct, general pathologies; an immune mediated and an
idiopathic form. The immune diagnosis is a result of an autoimmune attack on the
pancreatic beta cells rendering them unable to carry out their normal physiological
function o f insulin production. The second pathology, idiopathic, implies that the reason
for beta cell destruction in unknown, and is not associated with the production of
antibodies [9].
Type II diabetes accounts for the other 90% of the diagnosed cases and is a
dynamic disease characterized by a resistance to the affects of insulin leading to a
hyperglycemic state [9]. Unfortunately, according to national diabetes statistics, the
average onset o f type II diabetes precedes clinical diagnosis by several years [10]. To the
patient, this means that the detrimental affects of the hyperglycemic state will take place
prior to diagnosis and treatment. Over the past thirty years, a rising incidence in cases of
type II diabetes can be attributed to an increase in prevalence of obesity and a general
decline in physical activity [9]. Type 2 diabetes is characterized by an altered lipid profile
and an overall pro-inflammatory state. Both excess fat and diminished physical activity
are predisposing factors to type II diabetes, or more specifically insulin resistance. Insulin
resistance (IR) is defined as the inability o f peripheral tissue to take up endogenous
glucose in response to normal, circulating levels of insulin. The primary cause of the
common form of type 2 diabetes is not completely understood, but autoimmune
mechanisms are not involved [11]. Cellular resistance to the effects of insulin is a factor
in 60-80% of individuals with type 2 diabetes. Decreased beta cell responsiveness to
plasma glucose levels is observed, along with abnormal glucagon secretion and beta cell
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dysfunction and eventual beta cell “burnout”. The islet dysfunction may be caused by a
decrease in beta cell mass, abnormal function of the beta cells, alterations in the insulin
receptor, or post-receptor events. Pancreatic changes among type II diabetic patients tend
to be non-specific and in about 30% of these patients the changes are associated with
increased amyloid deposition which can also lead to islet cell destruction. On top of
detrimental pancreatic changes, liver changes related to elevated serum lipid levels are
also observed in type 2 diabetics. Pancreatic and hepatic atrophy, although observed in
diabetics and non-diabetics, occurs amongst diabetics with much greater frequency, and
this increase in fatty infiltrates may also play a role in the development of amyloid
deposits in the islets. Eventual pancreatic fibrosis also plays a role in loss of beta cell
function in about 50% of individuals with type 2 diabetes [11], This decreased beta cell
function leads to the advanced stages of type II diabetes characterized by decreased or
diminished insulin secretion, insulin resistance (IR) and hyperglycemia.

Dyslipidemia and the Metabolic Syndrome
The observation that IR, as well as a number of other risk factors, such as obesity,
hypertension and hypercholesterolemia are common in those who are predisposed to the
development of cardiovascular disease lead to the suggestion o f a metabolic syndrome, or
a group of symptoms that collectively indicate an increased risk to CVD. Much debate
and controversy has arisen over the idea of classifying a clustering of risk factors for
cardiovascular disease. It is still vague how the syndrome should be represented and how
the underlying mechanisms of the syndrome affect the predisposition to cardiovascular
disease[12]. Generally, the metabolic syndrome clusters hypertension, dyslipidemia,
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impaired glucose tolerance and obesity, which are all well established risk factors for
CVD. This clustered phenotype has been discussed since the 1980s as the “metabolic
syndrome”, but prior to that, as early as the 1930s, it was described as syndrome X, the
insulin resistance syndrome, and the deadly quartet [13]. More recently, due to the
concept of metabolic abnormality or dysfunction within the syndrome, some authors have
suggested the use of the dysmetabolic syndrome. There have been numerous attempts to
standardize the definition of the metabolic syndrome, but no final definition has been
established. One o f the most widely used definitions, developed by the World Health
Organization (WHO) in 1998 and revised in 1999, establishes that the human metabolic
syndrome requires at least one of the following: type II diabetes mellitus or impaired
glucose tolerance or glucose resistance. It also requires at least two of the following:
hypertension (BP > 140/90 mm Hg), obesity (body mass index [BMI] > 30 kg/m2, or
waist to hip ratio > 0.90 for male subjects or > 0.85 for female subjects), dyslipidemia
(low HDL-C cholesterol [<.90mmol/L] and/or hypertriglyceridemia (> 1.7 mmol/L), or
microalbuminuria (urinary albumin excretion rate > 20ug/min) [14]. The estimates of
current prevalence among various populations are alarming and projections are for future
increases. According to the National Health And Nutrition Examination Survey III
(NHANES III), from 1988 to 1994,24% of adult Americans older than 20 years had the
syndrome [15]. A recent study by Isomaa et al. reported that there is a 3-fold excess of
CHD and stroke in subjects with the metabolic syndrome phenotype [16]. It has been
estimated that 75% o f people with type II diabetes meet the criteria for the metabolic
syndrome, and many believe that obesity is a key etiologic factor in the development of
the underlying insulin resistance [17]. Much effort and time has been spent toward the
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therapeutic treatment of the individual components of the metabolic syndrome, and many
successful treatments have been developed. Physicians and pharmaceutical companies
have targeted high blood pressure for the treatment o f CVD for many years and have
been relatively successful at producing drugs efficient at lowering hypertension. With the
introduction o f statins and advice on total lifestyle changes (TLC), the medical world has
been able to target and decrease elevated LDL-C levels, but unfortunately these changes
have not lead to concomitant decreases in incidence of CVD. The reasons for this discord
are primarily unknown and have caused researchers to focus their studies on other risk
factors. More recently, effort has been put toward treating the other abnormalities
associated with dyslipidemia and insulin resistance; more specifically, a lower
concentration of serum HDL-C cholesterol that is observed in this state.

The HDL-C Hypothesis
Epidemiological studies have identified elevated LDL-C as an independent risk
factor for cardiovascular disease. Over the past ten years, clinical trials aimed at lowering
LDL-C to decrease CVD risk have plainly established that reductions in LDL-C are
associated with 30% to 40% reductions in clinical events [18]. Unfortunately, despite the
efficacy o f statins and other drugs in lowering serum LDL-C levels, many patients
continue to experience detrimental cardiovascular events. Because the efficacy of
targeting LDL-C to decrease CVD risk is still questionable, research has also been
directed toward pharmacological, genetic, and dietary manipulations to raise serum HDLC. Non-epidemiological studies have shown evidence that raising HDL-C could reduce
the risk o f CVD. One study, using transgenic animals that overexpress apolipoprtoein A1
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(apoAl), showed that increasing plasma HDL-C protected against diet induced and
genetically determined atherosclerosis [19]. In another study, infusion of HDL-C in the
form o f apoA-l/phopholipids complexes was associated with regression of
atherosclerosis in cholesterol fed rabbits [20]. This is important because by increasing
HDL-C, not only can physicians target the initiation and progression of the disease, but
they might actually be able to regress the progression of atherosclerotic lesions. In
another study, 5 weekly infusions of apoA-1 Milano/phospholipid complexes in healthy
men were shown to decrease total atheroma volume by 4.2% after an acute coronary
event using intravascular ultrasound to quantitate coronary atheroma. These results all
point at the fact that raising plasma levels of HDL-C could significantly decrease the
onset and outcome of severe cardiovascular events. More clinical trials need to be carried
out to measure surrogate endpoints of atherosclerosis, especially considering some of the
disappointing results o f the LDL-C trials after some promising initial results. If some of
the rate limiting enzymes or integral proteins involved in HDL-C synthesis and
processing could be up-regulated, hypothetically some of the associated risks of low
serum HDL-C could be diminished.
The next step towards development of therapeutic options based on increasing
HDL-C levels is understating the atheroprotective nature of the HDL-C molecule itself.
Although our knowledge of it actions are not complete, there is evidence to support at
least three atheroprotective mechanisms. HDL-C mediates the efflux o f cholesterol from
peripheral cells (eg: arterial macrophages) in order for cholesterol to be returned to the
liver for processing (breakdown and bile acid conversion). Cholesterol efflux from
macrophages within the atheroma to the HDL-C molecule can occur by passive diffusion
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[21], by combining with the scavenger receptor B1 (SR-B1) [22] or by binding to the
ATP Binding Cassette Transporter A1 (ABCA1) [23-25]. Nascent apoA is the preferred
acceptor for the ABCA1 transporter mediated cholesterol efflux which after esterification
o f free cholesterol to cholesteryl esters (CE) by lecithin cholesterol acyltransferase
(LCAT) is then converted to spherical a-HDL-C [26] (see figure 1). HDL-C is a pivotal
component o f the atheroprotective reverse cholesterol transport pathway, functioning as
the shuttle o f excess peripheral cholesterol to the liver for disposal as bile acids and
cholesterol. A second major mechanism by which HDL-C may be protective against the
progression of atherosclerosis is by protection of LDL-C from oxidation. Oxidatively
modified LDL-C, unlike normal LDL-C, is recognized by scavenger receptors CD36 and
SRA on macrophages resulting in the macrophage accumulation of CE and incidental
foam cell formation. Oxidized lipids are transferred from LDL-C to HDL-C and are
hydrolyzed by HDL-C paraoxonase and PAF acetylhydrolase [27]. A third mechanism by
which HDL-C may protect against the onset of CVD is the selective decrease of
endothelial cell adhesion molecules, which facilitate the binding of monocytes to the
vessel wall subsequently promoting lesion development [28]. In order to elucidate the
specifics o f these mechanisms, it is important to know some of the basics of
atherogenesis, and the role o f reverse cholesterol transport.

Pathogenesis of Atherosclerosis
The normal arterial wall consists of three well-defined concentric layers; the
innermost layer is the tunica intima, the middle layer is the tunica media, and the
outermost layer is known as the tunica adventitia. These three layers are separated by
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concentric layers o f elastin known as the external and internal elastic lamina. [3] The
luminal surface of arteries is lined by a single contiguous layer of endothelial cells that
rests upon a basement membrane superficial to the tunica intima. At one time,
atherosclerosis was thought o f as a passive process of lipid accumulation and plaque
formation causing the endothelial cells to reflexively protrude into the luminal space. It is
now known that atherosclerosis is a multi-factorial, dynamic process in which the
endothelial cells regulate a wide variety of functions in the arterial wall including
thrombosis, vascular tone, and leukocyte trafficking. Throughout the years,
atherosclerosis has been characterized in many ways including: a degenerative disease
process, a proliferative process and an accumulative process. One of the most widely
accepted views is the “response to injury” hypothesis which was modified and tested by
Russel Ross. This hypothesis implies that the lesions represent a specialized form o f a
“protective, inflammatory-fibroprliferative response to various forms of insult to the
arterial wall.” Depending on the extent and duration of the insult, the defensive response
may become chronic and excessive leading to a disease process [29].
In human atherosclerosis is characterized by three lesion stages: fatty streak,
fibro-fatty and advanced. Fatty-streak lesions are characterized by nodular areas of lipid
deposition; these early lesions, characterized by the development of macrophage ‘foam
cells’ typically start by the age of 10, and increase to involve as much a 1/3 of the aortic
surface in the third decade o f life [3]. The production of these lipid-loaded macrophages
which contain large amounts o f CE is a hallmark of both early and late atherosclerotic
lesions. The accumulation o f cholesterol in these cells is thought to be mediated primarily
by the uptake o f modified forms of LDL-C via scavenger receptors (e.g.,CD36 and SRA)
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[30]. Although there may be multiple proteins that aid in the cholesterol uptake,
scavenger receptors A (SRA) and CD36 have been shown to play significant, quantitative
roles. Research with Apo E-deficient mice lacking the SRA and CD36 receptors has
demonstrated that these animals develop significantly less atherosclerosis than control
Apo E knockout mice [31]. Cholesterol taken up by the macrophage via scavenger
receptors in the oxLDL-C form consists o f free cholesterol as well as lysosome
hydrolyzed cholesterol esters. Free cholesterol has a number o f metabolic fates, including
esterification by acyl coA: cholesterol acyltransferase (ACAT) as well as storage within
the lipid droplets that characterize foam cells. Cholesterol deposits within these lipid
droplets can in turn be hydrolyzed by cholesterol ester hydrolase, generating free
cholesterol for incorporation into membranes as well as for transport out of the cell. The
fate of cholesterol, once hydrolyzed, will be discussed in detail later, but involves two
main processes: enzymatic modification to more soluble forms and efflux via membrane
transporters.
As fatty streak lesions progress, there is a transition from the relatively simple
fatty-streak to a more complex lesion, which is characterized by the transmigration of
smooth muscle cells (SMCs) from the medial layer through the internal elastic lamina
and into the intimal, or subendothelial space. These smooth muscle cells, now located in
the intimal space have the ability to proliferate and take up modified lipoproteins, further
contributing to foam cell formation. These SMCs also begin to produce and secrete extra
cellular matrix proteins that strengthen and enlarge the plaque and form the beginnings of
the fibrous cap [32, 33]. The lesion has now entered a phase o f development that is
influenced by interactions between monocytes/macrohages and T cells that result in a
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wide range of humoral and cellular responses. The lesion is in a self-perpetuating chronic
inflammatory state: lesional T cells appear to be activated expressing both Thl and Th2
cytokines [34], Pro-inflammatory cytokines produced within the atheroma provide a
chemotactic stimulus to migrating leukocytes directing their adherence and migration into
the intimal space. Once these blood-derived inflammatory cells are resident in the arterial
wall, they sustain the local inflammatory response. As progression continues, T-cells are
further stimulated, encountering protein antigens such as oxLDL-C, heat shock protein 60
(HSP60), microbial antigens and simulataneous ligation of costimulatory receptors. The
antigenic stimulation causes them to elaborate the production of pro-inflammatory
cytokines such a y-interferon and TNFa. These cytokines can in turn stimulate
macrophages proliferatively and phenotypically as well as vascular endothelial cells and
SMCs. As this inflammatory process is perpetuated, the activated leukocytes and
endogenous arterial cells can release fibrogenic mediators including a variety of growth
factors that can promote proliferation of SMCs. As the SMCs proliferate and
concentration of fibrogenic mediators increases, so does the extent of elaboration of the
extracellular matrices becoming more characteristic of the advanced lesion.
Advanced lesions are characterized by a necrotic core, with increased calcified
fibrous areas of the artery with visible ulceration. Inflammatory processes not only
promote induction and evolution of the atherosclerotic plaque, but also contribute
definitively to the acute thrombotic complications of atheroma [35]. Although the
advanced lesion can lead to ischemic disease as a result of progressive narrowing o f the
arterial lumen, acute cardiovascular events that result in myocardial infarction and stroke
(the major sequella of lesion formation) are believed to result from plaque rupture that
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leads to thrombosis[36]. If the plaque is unstable and raptures, plaque material including
lipids and tissue factor (TF) are exposed to blood, initiating the coagulation cascade,
platelet adherence and thrombosis. The highly concentrated, activated macrophages
within the arterial lesion can produce proteolytic enzymes (e.g., matrix
metalloproteinases (MMPs)) that are capable of degrading the collagen and extracellular
matrix that aids in strengthening the plaque’s protective fibrous cap, rendering that cap
thin, weak and susceptible to rapture, y -interferon, also produced by activated
macrophages, can stop production of collagen by SMCs, limiting their capacity to further
produce strengthening extracellular matrix proteins. As the lesions further progress
toward the most advanced state, apoptosis and necrosis of lipid-laden macophages
becomes morphologically evident. The cell death going on within the arterial lesion can
result from cell to cell interactions and the highly concentrated cytokine environment; it
can involve the actions of pro- and antiapoptotic proteins that include death receptors,
proto-oncogenes, and tumor suppressor genes [37]. The release of insoluble and oxidized
lipids from necrotic cells leads to the formation of the extracellular lipid “gruel” seen in
advanced lesions.

Reverse Cholesterol Transport
Almost all animal cells synthesize cholesterol and import cholesterol from plasma
lipoproteins in order to maintain normal function. At any time, there is a dynamic
between the amount o f free cholesterol and CEs within the cell, which is regulated by
lipid metabolic enzymes: acyl-coenzyme A: cholesterol acyltransferase-1 (ACAT1) and
neutral cholesterol ester hydrolases (nCEH) also known as hormone sensitive lipase
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(HSL). To maintain cholesterol balance and prevent cholesterol overload, cells must
have the ability to export excess cholesterol. The only available reservoir for exported
cholesterol deposition is the liver, owing its unique ability to synthesize bile acids and to
transport cholesterol into bile. The process by which extrahepatic tissue controls the
balance o f cholesterol through its return to the liver is termed “reverse cholesterol
transport (RCT).” In order to further study some of the key mediators involved in this
protective mechanism in more detail, it is important to be able to understand the sequence
of events in the reverse cholesterol transport process. Extrahepatic tissues, such as arterial
tissue, synthesize cholesterol and also derive cholesterol through the uptake of
lipoproteins via the LDL-C receptor and scavenger receptors. The cholesteryl esters in
peripheral tissue are in a constant equilibrium with free cholesterol, through the opposing
actions of ACAT and neutral cholesterol esterase. Free cholesterol (FC) is extruded to
extracellular acceptors, most notably phospholipid/apoA-I disks (pre-J3-HDL-C). This
process is directly dependent on functional ABCA1, a membrane bound cholesterol
shuttle. Proper cholesterol loading is essential for the stability of HDL-C, the primary
lipoprotein involved in reverse cholesterol transport. In the absence of sufficient
cholesterol efflux, apoA-I is rapidly cleared from the circulation by the kidneys [38].
Cholesterol that associates with apoA-I/phospholipid disks is a substrate for LCAT,
which transfers a fatty acyl chain from phosphatidylcholine to cholesterol, forming CE.
The CE partitions into the hydrophobic core of the lipoprotein, thus forming spherical
HDL-C particles. These particles can than deliver CE to the liver as well as to
steroidogenic tissues. The interaction o f spherical HDL-C particles with the scavenger
receptor SR-BI leads to selective delivery of CEs, as the SRB1 receptor can only interact
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with spherical HDL-C particles. The CEs are hydrolyzed by a neutral cholesterol
esterase, providing free cholesterol for secretion across the apical (bile canalicular)
membrane o f the hepatocyte and for bile acid synthesis. (See Figure 1)

M a t u r e HDL-C
A-I

M acro p h ag e

N a s c e n t HDL-C
A-I

LCAT

idation

S teroidegenic
Tissue

VLDL- C/ LDL- C
Figure 1: Reverse Cholesterol Transport

Derivedfrom LipidsOnline.com

CE=Cholesteryl Ester, HDL-C=High Density Lipoprotein-Cholesterol, VLDL-Very Low
Density Lipoprotein, LDL-C=Low Density Lipoprotein, LDL-R= Low Density
Lipoprotein Receptor, FC=Free Cholesterol, SRBI=Scavenger Receptor B l,
SRA =Scavenger Receptor A 1, ABC A 1 =A TP Binding Cassette A l, LCA T=Lecithin
cholesterol acyltransferase, CETP=Cholesteryl Ester Transfer Protein.

Transcription Factor Control
Transcription factors comprise a family of structurally-related eukaryotic proteins
that are involved in the control of a large number of normal cellular and organismal
processes, such as immune and inflammatory responses, developmental processes,
cellular growth, and apoptosis. In addition, these transcription factors are persistently
active in a number of disease states, including cancer, arthritis, chronic inflammation,
asthma, neurodegenerative diseases, and heart disease. One factor, Nuclear Factor Kappa-
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P (NF- k B), has been implicated in the pathogenesis of both atherosclerosis and diabetes

mellitus, primarily due to its control of inflammatory gene expression [39]. N F- k B is a
protein heterodimer, whose activation can be stimulated by a number of factors
including: high glucose concentrations, free radical formation, TNF-a, radiation and
other stimuli. Some of the many downstream consequences of N F- k B activation include
transcriptional synthesis o f pro-inflammatory molecules and mediators of their
expression including: increased expression of adhesion molecules like VCAM-1 and
ICAM-1, tissue factor (TF) and the receptor for advanced glycation endproducts
(RAGE). Activation o f N F- k B occurs in endothelial cells exposed to high glucose levels
and low shear stress, but not in endothelial cells which are exposed to hyperglycemia
without decreased shear flow [40]. Due to decreased shear flow at lesion prone areas,
increased expression o f N F- k B at these sites might persist, leading to the increased
synthesis of proteins involved in atherosclerotic progression and inflammation including
VCAM-1. This inflammatory connection, could in part, explain the increased
atherosclerosis in diabetic patients. Therapeutic control of N F- k B might seem like a
promising option due to its involvement both in inflammatory control and atherosclerotic
progression; unfortunately specifically targeting vascular N F- k B is not currently an
option and complete inhibiton of this gene would have detrimental systemic side effects
[41].
The extensive knowledge of NF-kB signaling also exposes the extent of research
that still needs to be carried out in order to fully understand the pathway. Overexpression
studies in-vitro almost certainly do not accurately reflect physiological signaling events,
and more comprehensive studies looking at clinical endpoints need to be done. Studies in
16
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Drosophila have shown that very small differences in nuclear concentrations of these
factors, in their affinities for target DNA sites, and in cooperation or competition between
other transcription factors can have profound physiological consequences [42], In many
situations, it is not known how or which of the many genes induced by NF-kB in a given
response contribute acutely to that response. The development of methods to analyze
genome-scale changes in gene expression (e.g., cDNA microarrays), has already begun to
uncover additional NF-kB-responsive genes and has helped to clarify which NF-kB target
genes are activated in a given response. Earlier, unpublished work in our lab, by Gowdy
et al. established that the combination of a hyperlipidemic and hyperglycemic condition
in the Syrian golden hamster is associated with increased levels of mediators of
inflammation, specifically RAGE, VCAM, and NF-kB. This study sought to extend the
work by Gowdy et al., by determining expression of other inflammatory transcription
factors and their regulated proteins in the hyperglycemic Syrian hamster.

Peroxisome Proliferator Activated Receptors (PPARs)
Originally discovered as regulators of peroxisome proliferation in rodent livers in
response to xenobiotics, peroxisome proliferator activated receptors (PPARs) are now
known as members o f the nuclear receptor super-family of ligand-activated transcription
factors, which also include retinoic X receptor (RXR), and vitamin D receptor [43]. The
PPARs are among a group of forty-eight nuclear receptors in the human and mouse
genomes that have been discovered thus far [44]. The nuclear receptors are divided into
three groups based on the identification of known ligands. In general, these receptors
contain similar characteristics which include a ligand-independent transcriptional
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activation function domain (AF-1) located on the N terminus, a core DNA-binding
domain consisting of two highly conserved zinc finger motifs that are responsible for
binding the receptor to specific DNA sequences, a hinge region that allows flexibility of
the receptor to dimerize to other nuclear receptors and bind to DNA, a ligand binding
domain (LBD) and a second dimerization interface, and lastly a second ligand dependent
activation function domain (AF-2) at the carboxy terminus [45]. The three groups of
nuclear receptors segregated based on known ligands, their target genes, and their
physiologic function are: 1) the endocrine receptors, 2) the adopted orphan receptors, and
3) the orphan receptors. The PPARs are members of the “adopted orphan receptors,” that
once activated through ligand binding, undergo a conformational change, heterodimerize
with (RXR), and bind to PPAR response elements (PPRE) in the promoter region of
target genes, thus modulating genetic expression in either a positive or negative fashion.
The PPRE consists of a direct repeat of the consensus hexamer AGGCTA separated by
one or two nucleotides [46,47].
Three subtypes of PPAR exist (a, p/5, and y) encoded on separate genes and
exhibiting different tissue-specific distributions (See figure 2). PPARa is mainly
expressed in heart, muscle, kidney and liver; it is responsible for the regulation and
expression of genes involved in fatty acid oxidation. Fibrates are synthetic ligands of
PPARa used in the treatment o f dyslipidemia, while polyunsaturated fatty acids and
arachidonic acid metabolites, such as leukotriene B4 are natural ligands of PPARa.
PPARp/5 is the most ubiquitously expressed of the PPARs and also plays a role in lipid
metabolism, specifically within cardiac tissue [48]. O f the three subtypes, little is known
about PPARp/5 and much debate surrounds the role this transcription factor in the
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development and modulation o f atherosclerosis with strong arguments on both the proand anti- atherogenic sides. One study reported that treatment of LDL-C -/- mice with the
potent PPARp/S agonist, GW0742X, reduces atherosclerosis lesion burden, as well as
expression of pro-inflammatory proteins indicating the beneficial effects of agonizing the
p/8 receptor in the treatment of atherosclerosis [49]. Further studies assessing the ability
o f PPARp/5 agonists to diminish lesion stability and regress lesion size will provide more
information in the efficacy of targeting this receptor in treatment o f atherosclerosis.
PPARy encodes three major messenger RNAs (mRNAs) resulting from
differential promoter usage and alternative splicing that results in two different protein
isoforms differing in a 28 amino acid extension of unknown function at the amino
terminus [50, 51]. PPARy2 is mainly expressed in adipose tissue, whereas PPARy 1 is
found ubiquitously, including in the liver, heart, kidney, endothelium, vascular smooth
muscle cells, and macrophages, as well as other tissues. PPARy has been described as
having important roles in lipid metabolism, cellular differentiation, atherogenesis, and
glucose homeostasis[52]. PPARy’s involvement and importance in glucose homeostasis
is demonstrated by the fact that the insulin sensitizing thiazolidinediones (TZDs) are
synthetic high-affinity ligands of the PPARy receptor. TZDs are extremely important in
the treatment of type 2 diabetes due to their ability to promote insulin sensitivity. The use
of pioglitizone and rosiglitazone, two synthetic PPARy ligands, results in increased
peripheral glucose use, reduced hepatic glucose output, and improvement in overall
glycemic control. The activity of PPARs is primarily mediated by the binding of natural
and synthetic ligands, although its activity is not limited to ligand activation.
Transcriptional activity of the PPAR receptors can be influenced by other post-
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translational modifications such as phosphorylation and ubiquitination [53]. PPARs also
have the ability to transrepress multiple inflammatory pathways. This transrepression
involves interaction with coactivators and corepressors including such factors as NF k B,
AP-1, signal transduction activated transcription factors, CCAAT/enhancer-binding
protein and nuclear factor o f activated T cells. Still today, much work needs to be carried
out looking at the interactions of PPARy with other inflammatory transcription factors to
elucidate the pathways involved as well as to uncover future therapeutic targets.
Besides their effects on carbohydrate metabolism and overall glycemic control,
PPARy ligands have also been to shown to have beneficial effects on plasma lipids,
important molecules in the progression of atherosclerosis. PPARy is expressed in the
endothelium [54], macrophages [23], and human atherosclerotic lesions [55] and has
been shown to be expressed in almost every stage of atherosclerosis development and
progression (See table 1). As well as being expressed ubiquitously throughout
atherosclerotic tissue, PPARy agonists have also been shown to have pleiotropic vascular
effects. When PPARy agonists are administered for the treatment of type 2 diabetes, the
beneficial affects on cardiovascular disease risk may be attributed to the indirect affects
on insulin resistance, a direct inhibitory affect on atherogenesis and endothelial cell
dysfunction, as well as a potent antiinflammatory effect on molecules such as monocyte
chemoattractant protein-1 (MCP-1) and C-reactive protein (CRP). So, the ability of
PPARy and its agonists to regulate the atherosclerotic process might potentially be a
complex, coordinated interaction between the indirect effects of PPARy activation on
improving insulin sensitivity and reducing inflammation; this effect might also be
coupled with PPARy’s ability to regulate glucose and fat metabolism.
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Figure 2: PPAR Isoforms

Initial work by Marx et al.[56] brought attention to PPARy and its role in
atherogenesis. Further work by Marx observed increased expression o f PPARy within
both endothelial cells and vascular smooth muscle cells that were involved in
atherosclerotic plaques o f human coronary arteries [46, 57]. As stated, the initial concept
was that this inflammatory transcription factor is being activated in all o f the cell types
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involved in the development and progression o f atherosclerosis. The research began to
shift towards the reasons why PPARy was being expressed in the human atheroma. The
following year (1999), Yoshimoto et al. [58], using Wistar rats, clearly demonstrated that
PPARy ligands are powerful inhibitors of vascular smooth muscle cell proliferation and
that they may be a target for the treatment of neointimal hyperplasia. In early 2001,
Collins and associates proposed a mechanism for the atheroprotective effects of PPARy
and its ligands [59], demonstrating that troglitazone significantly reduced the number of
macrophages within atherosclerotic lesions in both nondiabetic and diabetic mice.
Rosiglitazone was also shown to limit lesion formation in LDL-C receptor deficient mice
[60], and similar results were reported in apoE knockout mice [61]. Therefore, PPARy
agonists seem to inhibit early lesion formation possibly through interference of monocyte
transendothelial migration with or without insulin resistance. Because PPARy was able to
exhibit similar effects in diabetics and nondiabetics, its ligands seem to have separate
antiatherogenic activities in addition to their insulin sensitizing effects. To further
elucidate these protective effects and the ability to use PPARy ligands as a therapeutic
tool, not only for the treatment of type 2 diabetes but also as a prophylactic for the
progression of atherosclerosis, one needs to asses the ability of PPARy ligands to affect
clinical endpoints o f atherosclerosis. One of the first clinical studies to evaluate the
effects o f PPARy agonists on atherosclerosis progression was performed using Japanese
patients living with type 2 diabetes. These patients were treated with either 30 mg/day of
pioglitzaone or placebo for six months and carotid intima thickness (IMT) was evaluated
at baseline, three months and six months post-treatment. In the placebo group, IMT
increased from baseline by an average of about 0.22mm over the six months while
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decreasing about 0.084mm in the treatment group. These differences were significant,
and demonstrated that PPARy agonist treatment could result in early inhibition of normal,
atherogenic processes[62].
PPARy has also been implicated in the mediation of inflammation and some of
the key players in the inflammatory process including CRP. It is well established that
inflammation plays a pivotal role in the atherosclerotic process promoting endothelial
dysfunction, which triggers a cascade of detrimental processes that lead to the formation
of the atheroma [63]. In a study carried out by Haffner et al., it was demonstrated that
after 26 weeks of Rosiglitazone treatment in patients with type 2 diabetes, concentrations
o f mean CRP, MMP-9, and WBC were all significantly decreased [64]. Rosiglitazone
had similar effects on CRP levels as well as fibrinogen levels in nondiabetic patients in a
study carried out by Sidhu et al., [62]. Several studies have confirmed that CRP, in
addition to being a powerful predictive biomarker, is also a mediator of atherosclerosis.
CRP has been demonstrated to decrease nitric oxide production, destabilize nitric oxide
synthase mRNA, increase endothelial cell apoptosis and increase NFkB expression [65,
66]. If CRP expression can be decreased through stimulation of PPARy, so can the
proatherogenic affects mediated by CRP. However, the debate over the involvement of
PPARy as well as CRP in the initiation and progression of the inflammatory process is
still a controversial one. As stated, PPARy is expressed in vascular smooth muscle cells,
endothelial cells, macrophages and T cells, all integrally involved in the inflammatory
cascade. The debate is not over whether or not PPARy is expressed in these cells, or even
whether or not it is involved in the regulation of the inflammatory response; these are
both accepted concepts. The debate stems from the question of whether or not PPARy is
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an anti- or pro- inflammatory mediator. PPARy specific ligands have been shown to
inhibit the expression of a host of inflammatory cytokines including TNF-a, interleukin
(IL) 1P and IL6 in monocytes [67], as well as inducible nitric oxide synthase, MMP-9,
and scavenger receptor 1 in macrophages [68]. In one study, PPARy ligands inhibited
angiotensin II (Ang II)-accelerated atherosclerosis in LDL-C -\- mice, whereas there was
no effect on lipid profiles, blood glucoses, or blood pressure. Intriguingly, the attenuation
o f Angll-accelerated atherosclerosis was correlated with a down regulation of the
proinflammatory transcription factor early growth response gene 1 (Egr-1) and several of
its target genes [69]. Due to the observation that while blood pressure and glycemic status
were unaffected, but progression of atherosclerosis was inhibited, one can tentatively
conclude that inhibition of inflammation plays a crucial role in the anti-atherosclerotic
affect of PPARy ligands. Further work elucidating some of the mechanisms behind the
antiinflammatory affects of PPARy as well as clinical endpoints of atherosclerosis needs
to be carried out in order to characterize PPARy’s effect on inflammation and how its
regulation of inflammation affects progression of atherosclerosis. Large-scale trials
examining the effects of PPARy ligands on clinical cardiovascular endpoints are
underway, but data is currently being collected from smaller clinical studies in patients
with type 2 diabetes. One such study demonstrated that troglitazone and pioglitazone
have potent inhibitory effects on the progression of carotid arterial intima-media
thickness [70]. Unfortuately, one cannot determine whether the antiatherosclerotic effect
observed post administration of the insulin sensitivity treatment was independent of the
antidiabetic effects of the drugs. Hypothetically, the reduction in intima media thickness
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was caused by a combination o f the antiinflammatory effects of the PPAR agonists as
well as the confounding effects of increasing systemic insulin sensitivity.
There is also one general effect of PPARy activation, not yet discussed, that could
also contribute to a decrease in atherosclerotic progression. Most diabetic patients also
live with an abnormal lipid profile or chronic dyslipidemia; in addition to endothelial
dysfunction, atherogenesis, and thrombosis, insulin resistance causes decreased uptake of
free fatty acids (FFA) by adipocytes [71]. Because of increased systemic FFA
concentrations, hepatic uptake of FFA also increases, which in turn increases hepatic
production o f triglyceride-rich lipoproteins, such as very low density lipoprotein (VLDLC), resulting in a dyslipidemic state. This increase in VLDL-C is also associated with
smaller HDL-C particles that are less efficient at the removal of CEs from peripheral
tissue including the arterial wall and lipid-laden macrophages. A rise in VLDL-C is also
associated with the smaller, denser more atherogenic LDL-C particles that are more
susceptible to modification such as oxidation.
The systemic increase in circulating atherogenic lipoproteins and the subsequent
rapid uptake leading to foam cell formation is the basis of the atherosclerotic disease
state. As stated earlier, at any time, there is a dynamic between the amount of free
cholesterol and CEs within the cell. Removal of cholesterol from lipid-laden
macrophages within the arterial wall theoretically could lead to the regression of
atherosclerosis or stabilization of the plaque. Stabilization of the plaque could prove
integral in prophylactically treating patients at high risk o f CVD; primarily because of the
detrimental results of plaque rupture (stroke, myocardial infarction and all ischemic
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diseases). Note the summary below of the effects of PPARy on general processes of
atherosclerotic development and progression (Table 1).
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The involvement of NF-kB, PPARs and other transcription factors in human
inflammation and disease certainly establishes them as targets for therapeutics. Indeed,
many common synthetic (e.g., aspirin), and traditional (e.g., green tea, curcumin)
remedies target, at least in part, the NF-kB signaling pathway. It is likely that our
knowledge o f the molecular details of these pathways will enable us to develop more
specific and potent NF-kB inhibitors. The power and control of these transcription factors
in the regulation of the pathology of many disease states is quite evident, which turns us
to some of the genes downstream that are activated through these cascades.
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ATP Binding Cassette Transporter A l (ABCA1)
Having the ability to enhance cholesterol efflux from foam cells and facilitate its
return to the liver for processing could potentially be a target for dug therapy in the
treatment of atherosclerosis. About 7 years ago, Bodzioch et al. [72] were able to identify
the molecular defect in Tangiers disease, namely ABCA1. Patients living with Tangier
disease (TD) present with low levels of HDL-C and increased sterol accumulation in
macrophages putting them at an increased risk for developing CVD. ABCA1 is a
membrane transporter abundant in macrophages and expressed ubiquitously that mediates
the cholesterol and phospholipid (PL) efflux to lipid poor apoAl, the precursor of HDLC, and hence plays a major role in reverse cholesterol transport and general cholesterol
homeostasis (see figure 3) [73].

Bile

LCAT

Liver

Mature HDL

ABCA1 _ £ £

Nascent HDL

Macrophage

Figure 3: ABCA1 in Reverse Cholesterol Transport [74]
CE=Cholesteryl Ester, HDL=High Density Lipoprotein, LDL-C=Low Density
Lipoprotein, FC=Free Cholesterol, SRBI=Scavenger Receptor B1, ABCA1 =A TP Binding
Cassette A l , LCAT—Lecithin cholesterol acyltransferase
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The structure of ABCA1 is characterized by the presence of two transmembrane
domains with six helices each, and a nucleotide binding domain containing two
conserved peptide motifs that are characteristic for the superfamily of ABC transporters.
The membrane transporter also contains two large extracellular loops joined by a
disulfide linkage which are throught to be important in the binding of apoAl. Cholesterol
efflux from the cell occurs through multiple pathways, ABCA1 being one of them. The
efflux o f FC promoted by ABCA1 is considered to be unidirectional and occurs through
active transport to apoAl, the most abundant apolipoprotein in HDL-C. Recent work
suggests that ABCA1 mediates simultaneous transport of FC and PL to apolipoproteins
based on the availability of different lipoproteins in the vicinity of the transporter itself;
the local discrimination o f ABCA1 may result in modification of the ratio of cholesterol
/phospholipid undergoing efflux. Recent work has also shown that affecting the
PL/apoAl ratio could play a major role in directing FC efflux through either the ABCA1
or the scavenger receptor B1 (SR-B1) pathway[75]. The apoAl concentration in the
extracellular fluid is dependent on synthesis, catabolism, and dissociation. A poA l’s
availability is also dependent on its reassociation with the lipoproteins in the plasma
compartment represented by the HDL-C fraction, which in turn could potentially
influence lipid efflux from the atheroma.
As stated earlier, the atherosclerotic plaque is a dynamic, multi-factorial
environment in which multiple mechanisms can affect its’ progression and stabilization.
Some o f these mechanisms that may be directly modified by the activation of ABCA1
include: altered extracellular matrix turnover, lipid accumulation and metabolism, and
alterations in cell turnover involving apoptosis and inflammation. Apoptosis, or
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programmed cell death, plays an important role in regulating and controlling cellular
turnover within atherosclerotic plaques. In order for the apoptotic process to be
successful as well as immunologically silent, the initial phase must be followed by an
efficient phagocytic phase. After initiation, phosphotidylserine (PS), an anionic
phospholipid which resides on the inner leaflet, is translocated to the outer leaflet which
allows the dying cell to be recognized by the phagocyte. ABCA1 was found to be
involved in promoting PS translocation and subsequent engulfment of the apoptotic cells
[76], This work illustrated that phagocytosis is impaired in ABCA1 deficient
macrophages and that forced induction of ABCA1 can cause engulfment by cells
normally not able to carry out the phagocytic process. The ability of ABCA1 to regulate
the apoptotic process, or at least induce the removal of dead cells that have undergone
apoptosis, presents a possible mechanism that can be targeted for the prevention of
progression and/or regression of the plaque. Advanced atherosclerotic plaques contain
high numbers of necrotic or dead cells, and enhancing the body’s ability to remove those
cells could aid in decreasing title severity of the atheroma.
Since ABCA1 also plays a putative role in inflammation, it may be involved in
the pathophysiology of atherosclerosis. A number of inflammatory mediators including
interferon-gamma (IFN-y), TNFa, and IL-1 have been reported to decrease the mRNA
and protein expression levels of ABCA1. It has been demonstrated that IFN- y can cause
a 3-fold downregulation of ABCA1 while simultaneously increasing AC AT activity, thus
promoting atherosclerosis. Also, IL-lp, an activator of matrix metalloproteinases
(MMPs) and other interleukins have also been reported to inhibit ABCA1 function thus
inducing cellular lipid accumulation [77], Although the role of ABCA1 in the transport
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and expression of the pro-inflammatory cytokines still needs further elucidation, it could
be speculated that a detrimental cycle might exist in which the initial activation of
macrophages and stimulation of cytokine release could cause ABCA1 deficiency. This
“relative deficiency” of ABCA1 could potentially lead to decreased clearance of
apoptotic and necrotic cells which in turn could further aggravate inflammatory
mediators leading to plaque instability. Based on its antiinflammatory and apoptotic
properties, therapeutic regulation of ABCA1 expression could be a promising target in
the treatment o f atherosclerosis [24].
As discussed earlier, removal of peripheral cholesterol from extra-hepatic tissue is
important in controlling the amount of lipid within the central core of the plaque. The
process of reverse cholesterol transport is carried out by ABCA1 dependent and
independent mechanisms. ApoAl that is regenerated from HDL-C, or secreted by the
liver, is lipidated by ABCA1 in peripheral tissue to form pre-p HDL-C which then can
collect cholesterol from extra-hepatic cells. It is also thought that cholesterol processed
from LDL-C uptake in the liver is transferred to HDL-C by hepatic ABCA1 to be
converted into bile for secretion, a process that is beneficial to atherosclerotic
progression. In the Framingham Heart Study [78], a 2-3 fold increase in cardiovascular
disease was observed in TD patients and obligate ABCA1 heterozygotes as compared to
age and sex matched controls. Another recent study found that patients with ABCA1
mutations had decreased amounts o f cholesterol efflux, lower HDL-C concentrations and
greater carotid-intima-media thickness as compared to matched controls [79].
Cumulatively, these studies imply a generalized anti-atherogenic effect of ABCA1 via its
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contribution to HDL-C formation while macrophage-bound ABCA1 provides a
peripheral anti-atherogenic effect on the vasculature.

PPARy and ABCA1: The LXR Connection
As discussed earlier, PPARy can work in concert with corepresssors and
coactivtaors, binding to DNA response elements in order to initiate a genetic response.
PPARy can heterodimerize with liver X receptor (LXR), another nuclear receptor
belonging to the same superfamily as PPARy. The LXR subfamily consists of two
members, LXRa and LXRp. LXRa is expressed in an auto-regulated and tissue-specific
manner, whereas LXRp is expressed ubiquitously. The LXRs are regulated (ligand
bound) by the oxysterols which appear to be produced in proportion to cellular
cholesterol content [80] and have been shown to play an important role in regulating
some o f the mechanisms that protect cells from increased cholesterol levels. LXRs also
positively regulate several intestinal and hepatic genes integral in cholesterol excretion
form the body, including Cyp'7, the rate limiting enzyme in bile acid synthesis as well as
ABCA1. PPARy can indirectly enhance cholesterol efflux by inducing the transcription
of LXRa and thus ABCA1. Consequently, the concentration of LXRa expressed in
macrophages within the plaque is important because of its ability to control ABCA1
dependent cholesterol efflux. LXRs ability to control cholesterol efflux is completely
dependent on ligand availability, which can be affected by endogenous homeostasis (i.e.,
increased fatty acids). LXRa has been shown to upregulate sterol regulatory element
binding protein-1 (SREBP-1) which results in increased unsaturated fatty acid synthesis.
Unsaturated fatty acids can promote ABCA1 degradation, indicating indirect negative
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regulation o f ABCA1 by LXRa [80]. This might not seem important, but could prove to
be in patients with insulin resistance and type 2 diabetes where increased levels of fatty
acids are observed. This degradation o f ABCA1 could in turn be counteracted within the
atherosclerotic plaque due to the oxysterol-rich environment which would activate LXRa
thus upregulating ABCA1. PPAR agonists, like the glitazones used in the treatment of
type 2-diabetes, have been shown in vitro to induce cholesterol efflux from macrophages
through the activation of ABCA1[81]. This control, interestingly, overrides the
inflammatory suppression o f ABCA1 by the cytokine IL-1(1 [77]. In terms of plaque
physiology, this could prove to be very important due to the increase in inflammatory
signals observed within the atheroma. Taken together, therapeutic regulation o f PPARy
could have positive independent and ABCA1 associated effects on the initiation and
progression of atherosclerotic disease in diabetic and non-diabetic patients.
The purpose of the current study is to examine the effects of hyperglycemia on the
atherosclerosis caused by diet induced hyperlipemia. The study will investigate one of the
major transcription factors of inflammation and lipid metabolism, PPARy, and how its
role in inflammation and reverse cholesterol transport may affect the development of
atherosclerosis. PPARy expression will be compared to ABCA1, an important trans
membrane protein involved in the shuttling of cholesterol from peripheral tissue back to
the liver for processing to determine whether this process is affected by the
hyperglycemic state.
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Objectives:
1. To determine if hyperglycemia is associated with accelerated atherogenesis as
indicated by plaque morphology in a hamster model.
2. To determine if the hyperglycemic state is associated with altered levels of expression
o f PPARy in vivo.
3. To determine if expression of hamster ABCA1 is correlated to increased hamster
PPARy expression in vivo.
4. To determine whether increasing expression of ABCA1 is associated with increasing
circulating levels o f HDL-C in hyperglycemic Syrian hamsters.
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CHAPTER 2
EXPERIMENTAL DESIGN

Forty-six Syrian FIB male hamsters were brought into the animal facilities and
allowed to acclimate for one week, after which four groups were established. Half o f the
hamsters (23) were given a high fat/high cholesterol diet with streptozotocin (STZ)
(hyperglycemic/hyperlipemic), while the other half was only fed the high fat diet
(hyperlipemic). One half o f the animals from each group were treated for 8 weeks, while
the other half were treated for 24 weeks. At each time point, hamsters were sacrificed and
blood was taken for total cholesterol, blood glucose, HbAlC, triglycerides, HDL-C
cholesterol and non-HDL-C cholesterol. Tissue was removed at time of sacrifice and
fixed for immunohistochemical analysis or frozen for Western blot and ELISA analysis
o f ABCA1 and PPARy.

Groups:

1. Hyperlipidemic (8 week Control)
2. Hyperglycemic/Hyperlipidemic (8 week Treatment)
3. Hyperlipidemic (24 week Control)
4. Hyperglycemic/Hyperlipidemic (24 week Treatment)
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Syrian Golden
Hamster (N=46)

Treated (STZ)(N=23)
(Hyperlipemic/Hyperglycemic)

Controls
(N=23)(Hyperlipemic)

8 weeksj

18 w eeks)

124 weeks]

Figure 4: Experimental Design
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I 24 weeks |

CHAPTER 3
METHODS AND MATERIALS
Animal Model
The FIB Syrian golden hamster (Mesocricetus auratus), as an animal model of
atherosclerosis, presents some unique characteristics that are normally unachievable in
other rodent models [82], Hamsters, when fed an atherogenic diet, develop predictable
lesions along the inner curvature of the aortic arch in a pathology similar to humans. One
hamster study observed fatty streak lesions developing within four weeks of the start of
an atherogenic diet and determined that the lesions were morphologically and
ultrastructurally similar to human fatty streak lesions [83]. Similar analyses of hamster
atherosclerosis have concluded that the lesion development in hamsters progresses
through similar stages of progression as compared to humans [84, 85]. Another advantage
of the hamster is that the serum cholesterol level increases observed on the atherogenic
diet corresponded to an increase in LDL-C and VLDL-C concentrations. This increase is
attributable to the fact that, in hamsters, LDL-C is the major plasma cholesterol carrier,
which is similar to humans [86]. This increase in LDL-C is not associated with an
increase in plasma HDL-C, concomitantly raising their TC/HDL-C ratio. Appropriately,
an elevated LDL-C value and a high TC/HDL-C ratio are both significantly associated
with the accelerated atherosclerosis seen in humans and the hamster on atherogenic diets
[83], From a practical standpoint, the hamsters are also inexpensive and relatively easy to
handle and care for.
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By administering STZ, a pancreatic P-cell toxin, the hamster has also been used to
study disease associated with a diabetic-like state [87, 88]. Briefly, STZ methylates DNA
and generates free radicals ultimately leading to the destruction o f the P-cells of the
pancreas, responsible for the production o f insulin. The STZ Syrian FiB hamster on a
high fat/high cholesterol (atherogenic) diet offers the ability to study the effects of
hyperglycemia on the development and pathology of atherosclerosis. STZ has been used
to induce a diabetic state in other animal models including the rat and pig [89, 90], but
due to their similarities to humans in both lipid profile and metabolism, the hamster may
be a more appropriate model to study the connections between diabetes, altered lipid
metabolism and accelerated atherosclerosis. The advantage o f the hamster was seen in a
study by Wang et al. in 2001, in which male Syrian Golden hamsters on a high fat diet
were given STZ to induce hyperglycemia. After just two weeks, free fatty acids (FFA),
triglycerides and glucose levels all dramatically increased; serum triglyceride was
increased by 7.3 fold, FFA by 4.2, and glucose levels by 91% [82], Due to their
similarities in the initiation and progression of atherosclerosis, both physiologically and
anatomically, the hyperglycemic hamster provides a unique model in which to study
human atherogenic progression in a hyperglycemic state.

Animals
Forty-six Syrian FjB male hamsters about 8 weeks in age were purchased from
BioBreeders Inc. (Fitchburg, MA) and delivered to the laboratory animal research facility
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at the University of New Hampshire. The hamsters were housed individually in plastic
rodent containers with ad libitum access to rodent chow (Purina 5001) and water and
maintained on a 12 hour light and dark cycle at 20+ 1° C. Following a one week
acclimation period, hamsters were randomly assigned to one of the four groups
1) 8wk control (C), 2) 8wk treated (T), 3) 24wk control (C) or 4) 24wk treated (T).
Following the one week acclimation, all hamsters (N=46), were fed Purina 5001 rodent
meal supplemented with 0.25% purified cholesterol (w/w) (Research Diets, Inc., New
Brunswick, NJ) and coconut oil 10% (w/w) (Spectrum Organic Products, Inc., Petaluma,
CA). The treated hamsters (N=23) were also given an intraperitoneal (IP) injection of
STZ (20mg/kg of body weight) (Sigma Chemical, St. Louis, MO) freshly prepared in
0.1M citrate buffer (pH 4.5) with a 22-gauge needle on a 3cc syringe (Becton Dickinson
& Co., Rutherford, NJ) one week after arrival at the animal facility. One week after the
STZ injection, hamsters were started on their respective diets and continued on those
diets for the duration o f the study (8 or 24 weeks). All experimental protocols were
approved by the Animal Care and Use Committee of the University of New Hampshire
(IACUC approval: 040706).
At sacrifice, hamsters were anesthetized using a closed chamber containing
isoflurane (Abbot Laboratories, North Chicago, IL). Once the hamsters were immobile,
they were removed from the chamber and anesthesia was maintained with a nose cone.
Foot reflex and jaw tone were checked to ensure that the animals were deeply
anesthetized. The abdomen was rinsed with 70% alcohol and an incision was made in the
abdomen through the peritoneum. The ribs were cut to the left o f the sternum and
hemostats were clamped to the edges of the sternum to expose the heart. Blood was
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drawn from the left ventricle o f the heart with a 22-gauge needle on a 3cc syringe
(Becton Dickinson & Co., Rutherford, NJ) and immediately placed into 1.3ml tubes
containing 35 I.U. of heparin (Sarstedt, Newton, NC). A small drop of whole blood
(~50uL) was used to measure HbAlC and blood glucose levels prior to aliquoting the
remaining sample. The samples were then inverted and centrifuged for 12 minutes at
1,500 x g in a table top Eppendorf 5415 microfuge (Brinkman Instruments, Inc.,
Westbury, NY). Following centrifugation, plasma was aliquoted into microtubes
(Sarstedt, Newton, NC) and placed on ice. The samples were stored in a -80° C freezer
(Revco Scientific Inc., Asheville, NC) until analysis.
Following the cardiac puncture, a small incision was made in the right atrium for
blood outflow, and a 21 gauge 1 inch butterfly needle was inserted into the left ventricle
to perfuse the circulatory system. Phosphate buffered saline (PBS) pH 7.4 was
continuously infused into the I.V for five minutes at physiologic pressure (110 mm Hg).
The fixed hamsters were then perfused for 10 minutes at physiologic pressure with
neutral buffered formalin (NBF). All hamsters were then placed on ice until dissection.
Both the aortas and the hearts were carefully removed from the formalin fixed hamsters.
During dissection, excess adventitia was removed from the aortas to prevent interference
during protein analysis. The heart and aorta were kept in-tact, and pinned at in-situ length
overnight in 10% NBF. After overnight fixation, the NBF was removed, and the aortic
arch was sectioned into three equal pieces (A, B, and C) (figure 5). Each section was
placed in a labeled, padded plastic tissue cassette to preserve morphology and rinsed in
ddH20 to wash tissue sections followed by storage in 70% alcohol until processing.
Sections were sent to the New Hampshire Veterinary Diagnostic Laboratory (NHVDL)
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where they were dehydrated in 100% EtOH and infiltrated with Paraplast Plus ™
embedding medium (Oxford Labware, St. Louis, MO) in the Tissue-Tex Automatic
Tissue processor (Miles Inc., Diagnostic Division, Tarrytown, NY) overnight. After
embedding in paraplast, each tissue section was trimmed and sectioned into 6 micron
slices and mounted onto Superffost/Plus glass slides (Fisher Scientific, Pittsburgh, PA)
for immunohistochemcial analysis.
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Figure 5
Segments of the Hamster Aortic Arch

Heart

Segments o f the hamster aortic arch: A, B and C are proximal, mid and distal sections
respectively. Sections B (mid section) was used for immunohistochemical and
histological evaluation and sections A, B and C were used for ELISA and Western Blot
analysis.
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Immunohistochemistry
Histologic sections from the B or mid portion between the two carotid arteries
from each treatment group were incubated with polyclonal antibodies against the antigens
for PPARy (GENE-TEX, San Antonio, TX) and ABCA1 (ABCAM, Cambridge, UK).
The PPARy antibody was generated in rabbits against a recombinant protein
corresponding to C-terminal amino acids 484-498 of PPARy 2. The ABCA1 antibody
was also generated in rabbits against a synthetic peptide: AETSDGTLPAP,
corresponding to amino acids 1201-1211 of human ABCA1. Reactivity was visualized
using the VECTASTAIN® Elite ABC Kit (Vector Laboratories, Burlingame, CA) for
both ABCA1 and PPARy. Briefly, slides were deparaffinized for 20 minutes in two
separate toluene baths (10 minutes each), then moved into a series of graded alcohols (10
minutes in 100% ethanol, 10 minutes in 95% ethanol), and re-hyrdrated in deionized
water for 10 minutes followed by a five minute rinse in PBS. Sections were then
incubated (for five minutes) in 3% hydrogen peroxide (American Procurement and
Logistics Co., Salt Lake City, UT) to eliminate endogenous peroxidase activity, followed
by a 5 minute rinse with PBS. Slides were than incubated at 80°C for 10 minutes with
Vector Antigen Unmasking Solution (Vector Laboratories, Burlingame, CA) to aid in
antigen retrieval. Nonspecific binding was blocked using normal horse serum provided
by the VECTASTAIN kit in a 10 minute incubation. Excess serum was blotted using a
Kimwipe™ and tissue sections were incubated overnight (18hrs) at 4°C. Serial dilutions
were performed in order to determine optimal primary dilutions for both ABCA1 and
PPARy; dilution was selected following microscopic evaluation of staining intensity and
background. All dilutions were prepared in PBS with 1% BSA and optimal

42

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

concentrations chosen were; PPARy, 1:500 and ABCA1: 1:50. Optimal primary and
secondary dilutions were determined through preliminary work carried out on practice
tissue and were chosen based on signal intensity and minimal background appearance.
For negative controls, aortic tissue from the hyperglycemic/hyperlipidemic group was
used. The treatment tissue was used because we anticipated a stronger antigenic signal as
compared to the controls. Negative controls were assessed using PBS, with 1% BSA in
lieu of the primary antibody. After overnight incubation, slides were washed for 5
minutes in PBS followed by a 30 minute incubation with provided biotinylated secondary
antibody (VECTASTAIN kit). Slides were rinsed for five minutes in PBS, followed by
application of an avidin and biotinylated horse radish peroxidase macromolecule complex
for 5 minutes followed by another 5 minute rinse in PBS. For visualization of reactivity
between the protein of interest and the corresponding primary antibody, the chromagen
3’-amino-9-ethylcarbazole (AEC) (Vector Laboratories, Burlingame, CA), which forms a
reddish color upon oxidation by horse radish peroxidase, was applied to the slides for 6
minutes followed by a 5 minute rinse in distilled water. Slides were counter stained with
undiluted Gil’s hematoxoylin for 30 seconds, (Vector Laboratories, Burlingame, CA)
rinsed under a gentle tap water stream, and immediately mounted with a glass coverslip
and aqueous mounting medium (Zymed, San Francisco, CA).
For morphological examination, B (mid) sections were stained with hematoxoylin
and eosin (H and E) following deparaffinization and rehydration by the New Hampshire
Veterinary Diagnostic Laboratory. Briefly, H and E staining allows for morphologic
examination through counterstaining between the nuclei and the cytoskeletal network;
hematoxoylin stains the nucleic acids (nuclei) blue and the eosin stains the cellulafr
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protein (cytoplasm) pink. All slides were examined and photographed using an upright
Olympus BH-2 light microscope attached to a digital camera (Qlmaging Corp, Burnaby,
Canada). Images were printed using a 7600 series Hewlett Packard printer (Hewlett
Packard Houston, TX) on Canon photo-quality printer paper (Canon, Tokyo, Japan).

Western Blot Protein Analyses

The fixed hearts, aortic arches, and descending aortas and hearts of the hamsters
were dissected and removed from the animal at the time of sacrifice. Any excess blood
was flushed with PBS and connective tissue was trimmed to avoid background signal.
The aortas to be cryo-preserved were cut away from the heart using a sterile razor blade
at the point o f attachment and placed into separate cryo-vials, flushed with nitrogen,
capped and snap frozen in liquid nitrogen. Frozen tissue sections, including aortas were
stored at -80° C (Revco Scientific Inc., Asheville, NC) until western blot and
transcription factor analyses were performed.
To determine expression of specific proteins within the lesion prone area on the
inner curvature o f the aortic arch, the thoracic aorta was removed from the heart with a
clean razor blade. The descending thoracic aorta was removed from the arch in line with
where the proximal portion of aortic arch ended. Western blot analyses for protein
expression of PPARy were performed on 1 aorta from each treatment group to confirm
expression. Aortas were processed and extracted on ice in the cold room at 4° C. To
remove excess blood the lumen of the aortas were flushed with PBS using a ICC syringe.
The aortas were minced using a cross-hatch pattern with two clean razor blades on glass
slides coated with aminoalkylsilane (Sigma Diagnostics, St.Louis, MO) to prevent tissue
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and protein adherence. After mincing, the aortic tissue was moved to a plastic microfuge
tube containing 500uL tris buffered saline (TBS) with protease and phosphatase inhibitor
mixture (Pierce, Rockford, IL). The aorta was then homogenized with a hand held Tissue
Tearor (Dremel, Racine, WI) set at level 30 for 3,15 second homogenizations with the
sample remaining on ice throughout the procedure. Following homogenization, samples
were kept on ice for 30 minutes, vortexing every five minutes. After homogenization,
samples were pelleted by centrifugation at 500 x g for 3 minutes and supernatant was
removed exposing the dry cell pellet in preparation for nuclear extraction. Nuclear
extraction was performed using the NE-PER nuclear and cytoplasmic Extraction kit
(Pierce, Rockford, II). Briefly, after concentration of the cell pellet, cytoplasmic
extraction reagent (CER) was added to the samples and vigorously mixed by vortexing at
the highest setting. After allowing the sample to incubate with the CER, samples were
centrifuged at 16,000 x g for five minutes and the supernatant fraction (cytoplasmic
fraction) was transferred to a clean, pre-chilled tube. The insoluble pellet, which now
contained nuclei, was vigorously mixed with the nuclear extraction reagent by vortexing
and allowed to incubate for 40 minutes. The samples were then centrifuged at 16,000 x G
for 10 minutes, and the supernatant (nuclear extract) fraction was transferred to a clean,
pre-chilled tube and stored at -80 °C until processing. To concentrate tissue samples,
aortic tissue was centrifuged, using a 10,000 molecular weight Microcon® centrifugal
filter tube device (Millipore Corporation, Bedford, MA), at 13,000 x G for 20 minutes at
4° C. Retentate was then collected via centrifugation at 1,000 x G for 3 minutes at room
temperature (RT). The protein concentrations of each sample were determined using the
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bicinchoninic acid assay (BCA) (Pierce, Rockford, U) at 450 nanometers on the ELX800
plate reader (BIO-TEK, Inc., Winooski, VT).
Following protein extraction and quantification, electrophoresis of the proteins
was conducted. Equal amounts of total protein were loaded into each lane of every gel for
all the aortic samples. The total amount of protein loaded for PPAR and ABCA1 was
approximately 7.0ug. Each sample was diluted 1:1 with 2X sample buffer (,5M TrisHCL, 10% sodium dodeclysulfate, 10% 2-mercaptoethanol, 20% glycerol and 0.02%
bromophenol blue) and incubated for 5 minutes in a water bath maintained between 95100°C. Positive controls, including 3T3 cell extract (Santa Cruz Biotechnology, Santa
Cruz, CA), and mouse liver lysate (Santa Cruz Biotechnology, Santa Cruz, Ca) were used
for PPARy. Samples were allowed to cool to RT and centrifuged to collect condensate
prior to loading. 10 uL of each sample was loaded onto 10% tris-HCL gels (Bio-Rad
Laboratories, Hercules, Ca). One lane each of Cruz Marker molecular weight markers (5
uL) (Santa Cruz Biotechnology, Santa Cruz, Ca) and Pierce pre-stained marker (5 uL)
(Pierce, Rockford, II) were also loaded onto each gel. A volume o f 15 uL of 3T3 cell
lysate and mouse liver lysate was loaded onto the gels. Gels were electrophoresed using
the Mini-PROTEAN Cell II® system(Bio-Rad Laboratories, Hercules, Ca) for about 50
minutes at 200 volts (Pharmacia Biotech, Uppsala, Sweden). Filter paper, pads and
nitrocellulose membranes (Bio-Rad Laboratories, Hercules, Ca) were equilibrated in cold
Towban buffer (25mM Tris, 192 mM glycine, 20% methanol, pH 8.3) for 15 minutes.
Protein transfer was performed for one hour at 100 volts (Pharmacia Biotech, Uppsala,
Sweden). Nonspecific binding was blocked by incubation of blots for one hour in 10%
(w/v) nonfat dried milk (Santa Cruz Biotechnology, Santa Cruz, Ca) in TBS (lOmM Tris-
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HCL, 150mM NaCl, pH 7.4) containing 0.05% (v/v) Tween-20 (TBST) (Bio-Rad
Laboratories, Hercules, Ca) on an orbital shaker set between 50-60 rpms at RT. Blots
were incubated overnight with primary antibody diluted in 10% (w/v) nonfat dried milk
in TBST at 4°C. Optimal primary and secondary dilutions were determined through
preliminary work carried out on practice hamster aortic tissue and were chosen based on
signal intensity and minimal background appearance. Specifically, goat anti-rabbit
PPARy (GENE-TEX, San Antonio, TX) was made up at a dilution of 1:1000 in 10%
(w/v) nonfat dried milk in TBST. After overnight incubation with primary antibody, blots
were washed with a 50ml TBST rinse, followed by 6, 5 minute TBST rinses on an orbital
shaker set at 60 rpms. Secondary antibody was diluted with 10% (w/v) non fat dried milk
in TBST at the following dilution; 1:10,000 for PPARy (donkey anti-goat
immunoglobulin G (IgG)- horseradish peroxidase (HRP), Santa Cruz Biotechnology,
Santa Cruz, Ca). Blots were incubated with secondary antibody for one hour at RT on an
orbital shaker. After incubation, 5, 5 minute 100ml rinses with TBST were performed
followed by one more rinse with TBS to minimize background signal during
development. West Pico chemiluminescence (Pierce, Rockford, IL) was applied at lOmls
per blot and incubated for 5 minutes. Blots were wrapped in Saran Wrap™, exposed to
CL-Xposure Film (Pierce, Rockford, IL) and the film was developed using a Konica
SRX-101 automated developer.

PPARy Transcription Factor Assay (ELISA)
In order to confirm expression and assess relative concentrations of PPARy, a 96
well enzyme-linked immunosorbent assay (ELISA) (Cayman Chemical, Ann Arbor, MI)
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was used with the nuclear extracts obtained from the aortic tissue. A specific double
stranded DNA (dsDNA) sequence containing the peroxisome proliferator response
element (PPRE) was immobilized on to the bottom of wells of a 96 well plate. Activated
PPARs contained within the nuclear extract, bind specifically to the PPRE. PPARy is
detected by the addition of a specific primary antibody directed against PPARy. A
secondary antibody conjugated to HRP is added to provide a sensitive, colorometric
reading of absorbance at 450nm. Because the assay was dependent on the binding of
PPARy to its corresponding response element within the well, the assay specifically
measured concentrations o f active, bound PPARy. The specificity o f the assay was
confirmed using non-specific binding (NSB) wells to confirm antigen specificity,
clarified cell lysate positive control wells, and competitive double stranded DNA (cDNA)
wells. Briefly, complete transcription factor binding assay buffer (CTFB) was prepared
with ddH20, provided assay buffer, and 300mM dithiothreitol (DTT). To the blank wells,
and NSB wells, lOOul of CTFB was added, while 90uls was added to the sample and
positive control wells, and 80ul was added to the cDNA wells. Following addition of the
CTFB, 10 ul o f competitor dsDNA was added to the cDNA wells followed by 10 ul of
the provided positive control which was also added to the positive control wells. lOul of
each sample was then added to the respective wells, and the plate was allowed to incubate
overnight at 4°C. The next day, following a series of washes with provided wash buffer
which contained Tween 20 (.5ml/L), primary (1:100) and conjugated secondary (1:100)
antibodies were added to all the wells, except for the blanks, and allowed to incubate for
one hour at room temperature. Finally, lOOul of developing solution was added to all
wells and allowed to incubate with gentle agitation at RT for 45 minutes. Before reading
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absorption levels, lOOul o f stop solution was added to halt the reaction. The plate was
then read at 450 nanometers on the ELX800 plate reader (BIO-TEK, Inc., Winooski,
VT), and results were expressed as both OD4 5o/ug protein and as a percent of the positive
control value.

Serum Assays
Plasma samples were removed from the -80°C freezer and thawed at RT. The
following assays were analyzed spectrophotmetrically on a Milton Roy
spectrophotometer (Milton Roy Compnay, Rochester, NY) in duplicate and duplicate
results averaged prior to statistical analysis. Total cholesterol was measured using the
cholesterol oxidase method (Pointe Scientific, Inc., Lincoln Park, MI). Samples that
exceeded 700 mg/dl were diluted 1:10 with physiologic saline (.9% NaCl) (The Butler
Company, Columbus, OH), vortexed, reassayed and the values multiplied by 10. This
was done to bring the measurement into an accurate portion of the standard curve.
Triglycerides were determined using the glycerol phosphate oxidase method (Pointe
Scientific, Inc., Lincoln Park, MI). Samples that exceeded 1000 mg/dl were diluted 1:10
with physiologic saline (The Butler Company, Columbus, OH), vortexed, reassayed and
the values multiplied by 10 to increase accuracy.
Since lipids can impede the transmission o f light and yield falsely high numbers, a
‘blank’ of the lipemic samples was prepared by mixing physiologic saline in lieu of assay
buffer with the plasma sample. After the blank was determined, the value was subtracted
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from the original values obtained in the assay for both the cholesterol and triglyceride
serum plasma assays.
HDL-C Assay
In order to obtain an accurate concentration o f serum HDL-C cholesterol, the
serum must be combined with a precipitating reagent in order to remove all of the beta
lipoproteins (LDL-C and VLDL-C). The HDL-C fraction remains in the supernatant
which is drawn off and treated as a sample to be assayed using the enzymatic cholesterol
method described above (Pointe Scientific, Inc., Lincoln Park, MI). Briefly, 500 ul of
hamster plasma was added to 500 ul of the polyethylene glycol precipitating reagent
(Pointe Scientific, Inc., Lincoln Park, MI), and vortexed thoroughly. The sample was then
centrifuged for 10 minutes at 2000 x g in a table top Eppendorf 5415 microfuge
(Brinkman Instruments, Inc., Westbury, NY). Supematent was drawn off and placed in
respective sample microfuge tubes to be assayed. HDL-C cholesterol was measured using
the cholesterol oxidase method (Pointe Scientific, Inc., Lincoln Park, MI), and analyzed
spectrophotmetrically on a Milton Roy spectrophotometer (spectronic (Milton Roy
Compnay, Rochester, NY) in duplicate and results averaged prior to statistical analysis.
Samples were standardized to a 50ug/ml HDL-C standard (Pointe Scientific, Inc., Lincoln
Park, MI).

Statistics
GraphPad Prism version V4.0 for Macintosh (Graph Pad Software, Inc., San
Diego, California) was used to perform a factorial analysis of variance (ANOVA)
followed by Tukey’s Multiple Comparison post test to compare groups for all serum
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assays and ELISA results. Data are expressed as the mean + standard error. Values of
p<0.05 were considered statistically significant.

Photo-documentation
Representative slides from the immunohistochemical analysis were examined and
photographed microscopically using an Olympus BH-2 microscope at 100X, 200X and
400X with a digital camera (Qlmaging Corp, Bumaby, Canada) and photo-documented
using QCapture version 1.2.0. (Qlmaging Corp, Bumaby, Canada). Images were printed
using a 7600 series Hewlett Packard printer (Hewlett Packard Houston, TX) on Canon
photo-quality printer paper (Canon, Tokyo, Japan).
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CHAPTER 4
RESULTS

Body Weights
At the beginning of the study, the hamsters weighed an average of 101.6 grams.
After 8 and 24 week periods, control groups weighed significantly more (p<.0001) than
their initial weight (Table 2, Figure 5). Although there was a trend of gradually increasing
weights amongst the treatment groups at 8 and 24 weeks, the differences were not
significant (p=.1537 for 8 week Tx and p=.4329 for 24 week Tx).

Selection of Hamsters Based on Response to STZ
Hyperglycemia in response to the i.p. STZ injection varies among animals as has
been documented in previous publications [87, 91]. Studies show a direct relationship
between HbAlC and average or mean plasma glucose (MPG) levels. For every 1%
change in human A1C, there is a change of about 35mg/dl in MPG. Due to wide
variations in MPG and more consistent A1C values, HbAlC levels were used to
determine the extent of the STZ response. For this study, hyperglycemia was defined as a
fasting HbAlC o f > 6%. The response to the STZ injection, based on elevated HbAlC
levels was significant as compared to the control groups who did not receive STZ
injections (p<.0001). Interestingly, the levels in the 8 week controls were significantly
elevated as compared to the 24 week controls (p<.05), but no difference was observed in
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the 8 week treated group as compared to the 24 week treated hamsters (Table 3, Figure
6).

Plasma Analyses

Lipids
The 8 week control group had the lowest mean plasma total cholesterol values
(879.1mg/dL), while the 24 week treatment group had the highest (2474.0mg/dL).
Compared to the 8 week control animals, plasma total cholesterol values were
significantly higher (2.6 fold) in the 8 week treatment animals (p<.01). The 8 week
control values were also significantly lower than the 24 week control values (p<.05) from
animals that consumed the same diet but for a longer period of time. Although there was
a trend of higher total cholesterol amongst the 24 week treatments as compared to the 24
week controls, the differences were not significant (p=.09). Between the 8 and 24 week
treatment groups, there were no differences and no correlative trends (Table 4, Figure 8).
Mean plasma triglyceride values were lowest for the 8 week control animals
(707.7mg/dL) and highest for the 8 week treatment animals (3884.0mg/dL) (Table 4,
Figure 9). The 8 week treatment group had a 5.5 fold increase for mean plasma
triglycerides compared to the 8 week controls which was a significant difference (p<.01).
Interestingly, there was almost a 2 fold decrease in the mean plasma triglyceride value in
the 24 week treatment group as compared to the 8 week treatment group, however, this
difference failed to reach statistical significance (p>.05). The mean triglyceride level for
the 24 week treatment group was two fold higher than the value for the 24 week controls,
but also failed to reach statistical significance (p>.05).
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HDL-C concentrations were lowest in the 24 week treatment hamsters (17.65
mg/dL) and highest in the 8 week control hamsters (57.63 mg/dL) (Table 5, Figure 10).
The 24 week treatment hamster values were significantly lower than all other groups
(p<.01). There was a 2.5 fold difference between the 24 week control and treatment
values, which were significantly lower (p<.001). Non HDL-C cholesterol values varied
from group to group, but exhibited an inverse relationship to the HDL-C cholesterol
values. The mean non HDL-C cholesterol value was 3 fold higher in the 8 week treatment
hamsters as compared to the 8 week control hamsters (p<01). The 24 week control
hamsters had a mean plasma non HDL-C cholesterol level of 1,273 mg/dL as compared
to a level of 2,547 mg/dL in the 24 week treatment hamsters which failed to reach
statistical significance (p=.08). The 8 week controls had significantly lower non HDL-C
cholesterol concentrations than the 24 week controls hamsters (p<.05). No significant
differences were observed when comparing the 8 and 24 week treatment groups. During
dissection, it was subjectively observed that the serum from both hyperglycemic groups
(8 and 24 weeks) was far more lipemic than the time matched hyperlipemic (control)
groups. One commonly used indicator of risk for cardiovascular disease is the ratio of
total cholesterol to HDL-C cholesterol levels. The 24 week treatment hamsters exhibited
the highest ratio (140.2), while the 8 week controls had the lowest (15.25) (Table 5,
Figure 11). The 24 week treatment value was significantly higher than the three other
groups (p<.0001).
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PPARy Expression (ELISA)
A PPARy transcription factor ELISA was performed and analyzed using nuclear
extracts form hamsters from all four groups. Results were expressed as % positive control
and as OD4 so/ug protein. No statistically significant differences were observed when
comparing treatment and controls within time points or when comparing controls and
treatment groups between time points for PPAR y expression, although presence of active
PPARy in all four groups was noted (Table 6).

PPARy Expression (Western Blot)
PPARy expression was not detected through Western Blot analysis. Thirty five
micrograms o f positive control (3TC cell lysate) was loaded and presence of PPAR y was
confirmed, but we were only able to load approximately 6.5ug of total protein (within
nuclear extracts) for each sample in each lane limiting our ability to confirm expression
among samples. One possible hypothesis for the lack of reaction seen among sample
groups was the minimal aortic tissue size, and even more limited protein concentration
following nuclear extraction.

Histology
Mid or B sections (Figure 5) of the aortic arch were examined to evaluate the
histology o f the aortic wall, and to characterize the stage of lesion development and
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relative size. The sections were processed, sectioned and stained with hematoxylin and
eosin by the New Hampshire Veterinary Diagnostic Laboratory (Figure 12, N=4).
8 week Control Group: In aortic sections from 8 week control hamsters (n=4) showed
few to no fatty streak lesions were observed. Normal morphology was observed with a
continuous monolayer of endothelial cells on top of an intact internal elastic lamina (IEL)
(Figure 12A).
8 week Treatment Group: Sections of aortic arch from 8 week treatment hamsters (n=4)
were examined for lesion development. Some early fatty streak lesions were observed
consisting of 1 to 2 layers of subintimal foam cell formation lining the periphery of the
luminal space (Figure 12B). The luminal endothelial cell architecture exhibited signs of
activation although the monolayer and IEL appeared to be intact.
24 week Control Group: In sections of aortic arch form 24 week control hamsters (n=4),
more advanced fatty streak lesions consisting of clusters of 2 to 4 foam cells, attached to
the endothelial monolayer, that began to protrude into the luminal space were observed.
Foam cells present within the lesions appeared to have increased lipid uptake represented
by increased foam cell cytoplasmic volume (Figure 12C).
24 week Treatment Group: Sections of aortic arch from 24 week treatment hamsters
(n=4) exhibited more developed and larger fatty streak lesions with clusters of 8 to 15
larger foam cells. Due to foam cell accumulation, lesions protruded well into the luminal
space and the nuclei o f the foam cells were displaced towards the periphery of the cell.
Both the endothelial monolayer as well as the IEL appeared to be intact (Figure 12D).
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Immunohistochemistry
Parrafin embedded sections of aortic arch for immunohistochemistry were
deparaffinized in toulene, rehydrated and reacted with primary antibodies for PPARy and
ABCA1. Positive immunoreactivity was monitored by the presence of red chromagen.
Representative samples from each group for PPARy are presented in figure 14, and
figure 15 for ABCA1. Representative negative controls for each antibody are presented
in figure 13.

PPARy
In the 8 week control group (Figure 14A), the smooth muscle cells exhibited a
diffuse immunoreaction for PPARy with dispersed chromagen deposition throughout
medial and intimal space. PPARy immunoreactivity in the 8 week treated (Firgure 14B)
hamsters was multi-focal and more intense as compared to the 8 week control hamsters.
However, the reaction in the treatment hamsters tended to be more localized to the foam
cells and prominent endothelial monolayer. The 24 week control hamsters (Figure 14C)
had a mild, focal reaction that was localized to the lesion and endothelial monolayer. The
24 week treated aortic sections (Figure 14D) exhibited a multi-focal, intense reaction in
the foam cells and a moderate reaction in the SMCs. Thus, although diffuse staining was
observed throughout the aortic sections in all groups, the reaction became more intense
with increasing development o f the lesions.
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ABCA1
Immunoreactivity for ABCA1 was present within aortas from all four groups. In
the 8 week control hamsters (Figure 15A), there was multifocal to diffuse
immunoreactivity for ABCA 1 within the endothelial and smooth muscle cells. A slightly
more intense reaction was observed in the 8 week STZ treated hamsters both in the
endothelial cells and SMCs. The 24 week controls (Figure 15C) had a mild multi-focal
reaction throughout the tissue section within all tunicae. Intense, diffuse
immunoreactivity was observed in the foam cells of the 24 week treated hamsters (Figure
15D), while moderate multifocal chromagen deposition was observed in the SMCs. Thus,
in 8 week treatment and control sections staining is moderately dispersed throughout the
endothelial and smooth muscle cell layers. Overall, as fatty streak lesion size increased,
there was a concomitant increase in immunoreactivity.
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Hamster Weights

Initial Hamster Weights
Group
(g)
93.9
8 week Control
8 week Tx
104.6
24 week
98.2
Control
109.5
24 week Tx
Table 2: Hamster Weights

Final Hamster Weights
(g)
122.9*
112.9

%of
Gain
30.9
12.9

130.6*
115.3

30.6
15.3

Values are mean + SEM. Values are analyzed for statistical significance
with an ANOVA with a Tukey’s Multiple Comparison test. Groups with
were significantly heavier at the end o f treatment (p<.0001).
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Serum Assays

Group
8 week Control
8 week Tx
24 week Control
24 weekTx

Glucose (mg/dL)
HbAlC (%)
289.6 + 34.4a
3.7 + 0.1a
364.8 + 21.2a
8 + 0.4b
223.4 + 21.2a
3.3 + 0.1a
7.1 + 0.4b
328.4 +31.3b

Table 3: Plasma Glucose and Hemoglobin A1C
HbAlC = Hemoglobin A1C

Group
8 week Control
8 week Tx
24 week
Control
24 week Tx

TRIG (mg/dL)
TC (mg/dL)
879.1 + 101.53 705.7 + 88.8a
2328 + 442.4b 3884 + 1057b
1172 + 93.0°
1425 + 160.3b
2474+ 543.4b 2193 + 791.8°

Table 4: Plasma Total Cholesterol and Triglycerides
TC = total cholesterol, TRIG = triglycerides,

HDL-C
Non-HDL-C Cholesterol
TC/HDL-C
57.63 + 18.93
807.3 + 110.43
15.25 + .005a
2292 + 437.9b
64.03+ .015b
36.36 + 5.6a
42.94 + 4.0a
1273+ 161.0°
33.19 + .095°
2547 + 592.5b 140.17 + .085d
17.65 + 3.3b

Table 5: HDUnon-HDL Cholesterol and Total Cholesterol/HDL Ratio
HDL-C = high density lipoprotein, TC=Total Cholesterol

Values are mean + SEM. Values are analyzed for statistical significance
with an ANOVA with a Tukey’s Multiple Comparison test. Groups with
dissimilar superscripts are significantly different (p<.05).
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Active PPARy Expression (Nuclear Extracts)

8 week
24 week
N=4
Control
8 week Tx
Controls
24 Week Tx
8.071 + 0.07 8.348 + 0.05
Averages (%Positive Control)
13.371 + 0.20
7.726 + 0.06
0.126 + 0.05
0.12 + 0.04
Averages (OD450/ug protein)
0.13 + 0.04
0.208 + 0.15
Table 6: Active PPARy Expression (ELISA Results)

Values are mean + SEM. Values are analyzed for statistical significance
with an ANOVA with a Tukey’s Multiple Comparison test. Groups with
dissimilar superscripts are significantly different (p<.05).
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Figure 6
Hamster Weights
Hamster Body Weights at
Initiation of Study

*v«v»v
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8wk
8wk
24wk
24wk
Controls Treated Controls Treated

Time

Final Hamster Body Weights at 8 or 24 weeks

8wk
8wk
24wk
24wk
Controls Treated Controls Treated

Time

Values are mean + SEM. Values are analyzed for statistical significance
with an ANOVA with a Tukey’s Multiple Comparison test. Groups with *
were significantly heavier at the end o f treatment (p<.0001).
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Figure 7
Hemoglobin A1C Values
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Time

Values are mean + SEM. Values are analyzed for statistical significance
with an ANOVA with a Tukey’s Multiple Comparison test. Groups with
dissimilar superscripts are significantly different (p<.05)
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Figure 8
Blood Glucose Concentrations
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Values are mean + SEM. Values are analyzed for statistical significance
with an ANOVA with a Tukey’s Multiple Comparison test. Groups with
dissimilar superscripts are significantly different (p<.05).
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Figure 9
Plasma Total Cholesterol Values
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Values are mean + SEM. Values are analyzed for statistical significance
with an ANOVA with a Tukey’s Multiple Comparison test. Groups with
dissimilar superscripts are significantly different (p<.05).
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Figure 10
Plasma Triglyceride Levels

5000«
4000h-1
T3 3000bb
H 20001IW00-

8wk
Controls

8wk

24wk

Treated

Controls

24wk
Treated

Time

Values are mean + SEM. Values are analyzed for statistical significance
with an ANOVA with a Tukey’s Multiple Comparison test. Groups with
dissimilar superscripts are significantly different (p<.05).
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Figure 11
Plasma HDL and Non-HDL Cholesterol Concentrations
HDL Levels
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Values are mean + SEM. Values are analyzed for statistical significance
with an ANOVA with a Tukey’s Multiple Comparison test. Groups with
dissimilar superscripts are significantly different (p<.05).
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Figure 12
TC/HDL-C Ratio
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Values are mean + SEM. Values are analyzed for statistical significance
with an ANOVA with a Tukey’s Multiple Comparison test. Groups with
dissimilar superscripts are significantly different (p<.05).
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Figure 13. Cross-sections o f hamster aortic arch (mid section (B)) at 8 and 24 weeks. No
lesions were found in the 8 week control sections (A). In the treatment group (8 weeks),
early fatty streaks consisting of one or two layers of subendothelial foam cells were
observed (B), as the endothelial cells are rested on a prominent, continuous internal
elastic lamina. Fully developed fatty streaks were present in the 24 week control hamsters
(C). In 24 week Hyperglycemic/Hyperlipidemic aortic sections, (D) advanced fatty streak
lesions consisting of several layers of foam cells were present causing a greater
protrusion into the luminal space. Again, the IEL remained intact. * indicates localization
foam cells. Photographed at 200X.
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Figure 14. Cross-sections o f hamster aortic arch (mid section (B)) at 8 weeks used as
negative controls stained for ABCA1 and PPARy. In lieu of primary antibody, arterial
tissue section was incubated with PBS with 1% bovine serum albumin. (A) is a
representative negative control for ABCA1, while (B) is a representative negative control
section for PPARy. Sections were counterstained with Mayer’s hematoxylin.
Photographed at 200X.
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Figure 15. Cross-sections of hamster aortic arch (mid section) immunoreacted with a
polyclonal antibody for PPARy. 8-week control (A) had multifocal immunoreaction for
PPARy throughout endothelial cells and smooth muscle cells of the tunica media. A more
prominent reaction is observed in the 8-week treatment group (B), with intense
immunoreactivity infoam cells and endothelial layer. In the 24-week controls (C), there
was moderate, localized immunoreactivity in foam cells and endothelial layer. The 24
week hyperglycemic group (D) had a intense, multi-focal reaction in the foam cells and a
moderate reaction in the medial SMCs. All sections were counterstained with Mayer’s
hematoxylin. Photographed at 200X.
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Figure 16. Cross-sections o f hamster aortic arch (mid section) immunoreacted with a
polyclonal antibody for ABCA1. 8-week controls (A) had multifocal immunoreaction for
ABCA1 throughout the endothelium and smooth muscle cells of the tunica media.
Intense, multifocal to diffuse immunoreactivity for ABCA-1 was evident in the 8-week
treated group (B) in the endothelial cedis and throughout the tunica media and adventitia.
The 24 week controls (C) had a mild, multi-focal reaction throughout all tunicae. The 24
week treatment group (D) had intense immunoreactivity in the foam cells and moderate,
multifocal immunoreactivity in the tunica media. All sections were counterstained with
Mayer’s hematoxylin. Photographed at 200X.
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CHAPTER 5
DISCUSSION
Hyperglycemia, one pathology found in both type I and type II diabetes
accelerates the process of atherogenesis in both human patients and animal models [92].
Although the exact mechanism(s) by which hyperglycemia accelerates atherosclerosis is
unknown, one possibility may be that the hyperglycemic state effects the activation of
inflammatory transcription factors involved in atherogenesis and the progression of
atherosclerosis. Hypercholesterolemia, a major risk factor for atherosclerosis, causes
focal endothelial activation. When plasma levels of cholesterol-rich LDL-C and VLDL-C
become elevated, the lipoproteins infiltrate the artery wall to an extent that surpasses the
capacity for removal causing retention within the extracellular matrix [93]. Inflammatory
transcription factors, activated upstream, which control genes involved in lipid
metabolism may accentuate or attenuate this process of cholesterol deposition and
atherosclerotic initiation. This is an initiating step in atherogenesis, which if controlled,
could lead to diminished progression of atherosclerosis.
In a hamster model of hyperlipemia and combined hyperlipemia and
hyperglycemia, we sought to determine how inflammatory transcriptional control
involved in the development of atherosclerosis would be affected by hyperglycemia and
if it would affect the initiation and progression of atherosclerosis. In the FiB strain of
Syrian golden hamster, feeding a high fat/high cholesterol (atherogenic) diet caused
atherosclerotic lesion development in a predictable manner, and with a morphology and
pathology similar to humans [83, 94], In order to create an atherogenic rodent chow,
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0.25% cholesterol and 10% fat was added to the chow (w/w). The atherogenic rodent
chow contained 23.5% calories from protein, 26.3% calories from fat, 50% calories from
carbohydrates and 32.4 mg (.27% w/w) cholesterol. Adding fat and cholesterol to the
rodent chow not only promotes the development of atherosclerosis, it also makes the diet
more comparable to a typical Western diet. Although the fat and cholesterol content of
the hamster diet contains 8% less calories from fat than the typical Western diet, and only
12% o f the cholesterol provided by a Western diet, the atherogenic diet correlates more to
the “typical American diet” than the normal rodent chow. Fat and cholesterol are
frequently added to rodent chow in order to increase insulin resistance and promote the
development of atherosclerosis [82,95, 96]. In one study, after feeding an atherogenic
diet for just ten days, total cholesterol, triglycerides and LDL-C levels were all
significantly elevated while HDL-C cholesterol decreased in a fashion similar to that seen
in humans [82]. It is important to note that the levels o f LDL-C cholesterol, the major
plasma cholesterol carrier in both the hamster and humans was significantly elevated
making them more prone to developing atherosclerosis. Hyperglycemia can also be
induced in the Syrian golden hamster through administration of STZ. The hyperglycemic
hamster fed a high fat diet provides a unique model to investigate atherosclerosis under
“diabetic-like” conditions [87, 90].
With exception o f the 8 week control hamsters, all other groups exhibited fatty
streak lesion development to varying degrees. In a few hamsters, occasional clusters of
foam cells were present, however, in most of the 8 week controls no foam cells or cell
pathologies were visible in any of the aortic sections, and it appeared that the hamsters
maintained normal endothelial morphology. In the 8 week treatment hamsters, the
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endothelial cell architecture was beginning to become more prominent, a sign of
activation, although the monolayer and IEL seemed to be intact. At 8 weeks, the
hyperglycemic hamsters exhibited early fatty streak lesions, consisting of 1 to 2 layers of
subintimal foam cell formation, as has been previously described [83]. The presence of
early fatty streak lesions in the 8 week treatment hamsters as compared to the 8 week
control hamsters suggested that, even at early stages, hyperglycemia, elevated TG, TC or
perhaps all three accelerated atherogenesis in this lipemic hamster model. These
morphological differences in lesion development were more pronounced in the 24 week
hamsters. The 24 week control hamsters had more extensive mature fatty streak lesions
that protruded into the vessel lumen while the 24 week treatment hamster, due to
increased lipid uptake, exhibited lesions that protruded into the luminal space with foam
cell nuclear displacement. Once again, due to differences in lesion development between
the 24 week groups, it appeared that the hyperglycemic conditions and associated altered
lipid levels were accelerating lesional progression. To see if the different conditions
would affect levels of transcriptional regulators of inflammation, immunohistochemistry
(IHC), western blot (WB) and ELISA analyses were performed for the two proteins
PPARy and ABCA1 which are both associated with lipid metabolism and atherogenic
progression [24, 80].
In this study, the 8 week treatment hamsters had significantly higher total
cholesterol values than their time matched controls (p<.01) placing these hamsters at
greater risk for developing atherosclerosis. A similar trend was observed for total
cholesterol values amongst the two 24 week groups, although the difference failed to
reach statistical significance (P>.05). This discordance could be attributed to the extreme
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hyoerglycemic state (based on elevated BG and HbAlC levels) induced in the 24 week
treatment hamsters leading to hypophagia. This decrease in total cholesterol was
associated with a concomitant decrease in HDL-C cholesterol exhibiting a possible
reason why these diabetic hamsters might have an increased risk for developing CVD.
Interestingly, the molar concentration o f HDL-C, which contains relatively more protein
and phospholipid than LDL-C, is similar to that of LDL-C in the plasma and, because of
its smaller particle size, HDL-C is the predominant lipoprotein species in the tissue. Also,
it has been shown in older men and women of any age that the inverse relationship of
CHD risk with HDL-C is generally stronger than the direct relationship with LDL-C [97].
By assessing fluctuations in HDL-C levels in diabetic patients, physicians may be able to
assess the level of risk for developing cardiovascular disease. HDL-C levels in the 24
week hyperglycemic hamsters were significantly lower than all of the other hyperlipemic
hamsters providing a possible reason for increased CVD risk amongst diabetic patients.
Clinically, physicians often not only rely on levels of total cholesterol and HDL-C
cholesterol as indicators o f CVD risk, but also the ratio between the two[98]. The
TC/HDL-C ratio followed the expected trend for CVD risk, as it was highest in the 24
week treatment hamsters and lowest for the 8 week control hamsters. The elevated
TC/HDL ratio in the 24 week treatment hamsters provides further evidence for the added
adverse effect of hyperglycemia over time. Plasma triglyceride levels were significantly
elevated in the 8 week treatment hamsters as compared to the 8 week controls, an
expected result in individuals with diabetes [2]. Fasting plasma triglycerides were also
significantly elevated in both 24 week groups as compared to the 8 week controls,
exposing them to an increased risk of developing atherosclerosis [38, 99]. This increased
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risk associated with elevated triglyceride levels may be attributed to the fact that
triglyceride-rich VLDL contribute to the formation of small, dense, atherogenic LDL-C
particles. These dense LDL-C particles are not readily cleared by LDL-C receptors
causing them to remain in circulation and within peripheral tissue where they are more
susceptible to oxidative modification [100]. The hypertriglyceridemic state observed in
the hyperglycemic hamsters contributes to the formation of atherogenic LDL-C through
increased transfer of cholesterol to LDL-C. Additionally, high triglyceride levels increase
VLDL-C secretion form the liver resulting in the exchange of TGs from VLDL-C for
cholesterol esters in HDL-C. The triglyceride in the HDL-C particle can be hydrolyzed,
which reduces particle size and can affect the binding of the associated HDL-C protein,
ApoA-1. Once affinity for ApoAl is decreased, it may dissociate from HDL-C where is
susceptible to metabolism by the kidney [100]. This mechanism contributes to the low
levels of HDL-C observed in diabetics with elevated triglycerides [38, 99]. To
summarize, elevated triglycerides leads to the formation of atherogenic LDL-C and
decreased HDL-C concentrations putting the hyperglycemic hamsters at in increased risk
for developing atherosclerosis; this implies that elevated glucose alone can not explain
the increased risk.
An intraperitoneal injection o f STZ was used to induce hyperglycemia in both the
8 and 24 week treatment groups. STZ is a pancreatic |3-cell toxin that causes necrosis or
marked degenerative changes in the pancreatic P-cells with nuclear pyknosis and
cytoplasmic vacuolization. It has been shown to produce diabetes mellitus in various
species including the Syrian hamster [101,102]. Interestingly, most species have a high
acute mortality to the STZ injection, whereas the Syrian hamster exhibits a high survival

81

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

rate from STZ induced hyperglycemia [103]. STZ is a methylnitrosurea that is taken in
by rodent P-cells possibly by a glucose transporter molecule. In cells, STZ toxin is an
alkylating which causes DNA strand breaks activating poly(ADP-ribose) synthase and a
subsequent lethal deletion of p-cell nicotinamide adenine dinucleotide (NAD). Previous
studies have also attributed the P-cell breakdown to oxidative stress through the
formation o f reactive oxygen species (RQS); this effect is further amplified by low levels
of antioxidant present within P-cell DNA [104], Regardless of the mechanism involved,
the result of STZ injection is elevated blood glucose levels as a result of DNA strand
breaks that are lethal to the insulin producing P-cells.
STZ treatment successfully induced a state of hyperglycemia in both 8 and 24
week treated groups. This effect was evident by the significant increase in fasting HbAlC
levels in these groups as compared to the control (hyperlipemic) hamsters (p<.0001). The
8 and 24 week control groups had mean plasma HbAlC levels of 3.7 and 3.3 %
respectively, whereas the hyperglycemic groups at 8 and 24 weeks had mean HbAlC
levels of 8.0 and 7.1% respectively (Table 3). HbAlC levels reflect the degree of
glycation on hemoglobin and subsequently blood glucose levels over the past 3-4 months.
Because of this, we were able to get an accurate assessment o f the glycemic state of the
hamsters for the duration o f the study, not just at the time they were sacrificed. This is
important due to the extent o f stress during sacrifice. Anesthesia principally affects
glucose metabolism through the modulation of sympathetic tone; however, in vitro
evidence exists that insulin secretion is suppressed by inhalational agents. The insulin
deficiency as a result o f the anesthesia compounds the absolute insulin deficiency present
in persons with diabetes, raising the risks of hyperglycemia and ketogenesis [105]. This
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effect could result in abnormally high glucose levels in both treatment and non-treatment
hamsters during processing. The statistically significant differences in HbAlC levels
accurately confirmed that STZ treatment resulted in elevated plasma glucose levels in the
treatment groups during the duration of the study. Blood glucose values were far less
consistent than the HbAlC values and are only able to depict a “snapshot” of the blood
glucose concentration at the time the blood is drawn.
In order to determine whether the hyperglycemia and abnormal lipid profiles
correlated to expression of the inflammatory transcription factor PPARy,
immunohistocemical, ELISA, and western blot analyses were run to determine its general
expression as well as expression of its active form. Various studies have indicated the
importance of PPARy and its function in metabolic homeostasis and inflammatory
control, including three studies that independently reported loss-of-function mutations in
the ligand binding domain of human PPARy [106-108]. These individuals harbor
dominant-negative mutant PPARy alleles that impair PPARy function by greater than
50%. A summary o f clinical features amongst these individuals include: early
atherosclerosis, dyslipidemia, early hypertension, limb/gluteal lipodystrophy, severe
insulin resistance, polycystic ovaries and hepatic steatosis. Most of these subjects had
marked and sometimes extreme dyslipidemia that was characterized by high TG and low
HDL-C levels, a phenomenon that we observed in our hamsters specifically in the treated
groups. This raises the question of whether individuals with hyperglycemia also have
modified expression of PPARy. As stated earlier, a crucial indication of the importance of
PPARy was highlighted when it was discovered as the cognate receptor for the insulin
sensitizing TZDs [109]. We questioned whether the effects of PPARy activation were
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important outside o f its clinical role as a receptor for TZD ligand activation. Are
endogenous levels o f PPARy affected by glycemic status? Unfortunately, no differences
were observed when we ran an ELSIA of representative samples to assess active PPARy
expression although presence of active PPARy was noted in each group. Although the
results from the immunohistochemical analysis are technically not quantitative, it was
observed that the reaction became more intense with increasing development of the
lesions. Because PPARy is expressed in adipose tissue, and developing lesions are
characterized by influx of lipid, this could possibly explain the increase in
immunoreactivity in the developing lesions; the extremely elevated TG levels could also
provide substrate for PPARy activation. In addition to being present in adipose tissue,
PPARy is also present in skeletal muscle, as well as within atherosclerotic lesions[45].
Thus, the effects o f PPARy activation on atherosclerosis are both indirect, improving
insulin sensitivity, and direct, affecting gene expression in the vessel wall, or more
specifically within atheromic macrophages. PPARy activation regulates both pro- and
antiatherogenic genes involved in cholesterol homeostasis. PPARy was found to
stimulate transcription of the CD36 gene which is a macrophage scavenger receptor that
traditionally contributes to foatm cell formation and development of atherosclerosis in
mice [110]. In concert with the finding that PPARy can be activated by the fatty acid
metabolites 9- and 13-hydroxyoctadecadenoic acids (9- and 13-HODE) present in
oxLDL-C, a PPARy cycle has been proposed in which oxidized lipids would induce
activity of PPARy, leading to the increased expression of CD36, which in turn would
increase oxLDL-C uptake. This process would prove detrimental in the progression of
atherosclerosis by promoting foam cell formation. PPARy has also been shown to induce
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expression of LXRa, thereby stimulating expression o f ABCAl-depednent cholesterol
efflux. Hypothetically, an even more complex cycle might exist in which there is a
concomitant increase in CD36 and ABCA1 resulting in clearance of the detrimental lipid
within the atheroma to resident macrophages for removal by ABCA1 back to the liver. If
these genes were co-stimulated in the manner described, upregulation o f PPARy would
prove beneficial in slowing and possibly reversing lesion progression. In order to test this
hypothesis, this study analyzed expression o f endogenous lesional ABCA1 expression
through immunohistochemical analyses. Although we did not obtain any quantitative
results, similar to the immunoreactivity for PPARy, ABCA1 reactivity became more
intense with increasing development of the fatty streak lesions. Immunoreactivity tended
to increase over time (8 to 24 weeks) and with initiation of treatment (STZ). ABCA1
expression and activity at the macrophage and hepatic levels is critical regarding lipid
efflux and HDL-C formation which in turn could influence the progression of
atherosclerotic plaques. Interestingly, the lowest levels of HDL-C were found in the 24
week treated hamsters, but the most complex lesions were also observed within this
group. This begs the question of whether there really is an increased concentration of
ABCA1 with increasing complexity of the lesion, and if so, why are HDL-C levels still
declining? One possible explanation is the extreme nature with which the lipid profiles
were altered. Although activated PPARy was detected by ELISA in all groups, there were
no statistical differences between them. However, average 8 week treated values were
higher than 8 week controls and 24 week controls were higher than both 8 week control
and treated aortas. PPARy may have the ability to act like a “lipid sensor”, gauging
changes in endogenous cholesterol homeostasis. In the hyperglycemic state, lipid profiles
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are altered, and concentrations of circulating FFAs are increased. This increase in FFAs,
which are endogenous ligands of PPARy, could stimulate activation of PPARy, causing a
downstream upregulation of ABCA1. This mechanism would be activated in times of
dyslipidemia as an attempt to positively influence lipid profiles (stimulate HDL
formation). But, upregulating ABCA1 could lack a downstream effect due to the extreme
alterations observed in the treated animal’s lipid levels. Overall, the PPAR-LXR-ABCA1
cascade has a significant role in cholesterol homeostasis and inflammation and there is
promising potential for therapeutic manipulation outside of the insulin sensitizing effects
o f TZDs. Further work needs to be carried out in which other functions of PPARy and the
cholesterol transporter ABCA1 as well as their pathways are elucidated so that strategies
can be developed to prevent atherosclerotic disease and its extensive complications.

Summary:
We found that hyperglycemia and associated altered lipid profiles amplifies the
negative effects of a hyperlipidemic diet through increased total cholesterol levels, non
HDL-C levels, triglycerides and decreased HDL-C levels. In the present study, hamsters
fed the high fat/high cholesterol diet developed early fatty streak lesions consisting of 1
to 2 layers o f foam cells. How ever, the hamsters that were also treated with STZ
developed hyperglycemia and larger, more developed lesions. Lesions characteristic of
the 24 week treatment hamsters invaded the luminal space of the aorta due to increased
lipid accumulation within larger foam cells. One observed possibility for the increase in
atherosclerosis in the treated hamsters was the significantly decreased levels of serum
HDL-C, the lipoprotein responsible for RCT. Decreased levels of HDL-C might slow the
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process of lipid removal from peripheral tissue (e.g. arterial lesions) for processing in the
liver. In order to analyze other mediators of the reverse cholesterol transport pathway,
this study observed expression of ABCA1. The expression of ABCA1, based on IHC
immunoreactivity, seemed to increase with developing complexity of the lesion and with
time. Overall, based on IHC immunoreactivity, the 8 week treatment and control sections
exhibited staining that was moderately dispersed throughout the endothelial cells and
tunica media. As treatment time increased and subsequently lesion size, ABCA1
expression tended to intensify and localize to lipid laded foam cells. This possible
increase could represent a feedback mechanism in response to the elevated concentrations
of lipid. This study also analyzed expression of the inflammatory, nuclear transcription
factor, PPARy which has been shown to regulate ABCA1 as wells as other pro- and
antiatherogenic genes [45], Based on our investigation, active PPARy expression did not
change with fluctuations in glycemic status (without TZD treatment), as we did not find a
difference in expression in our treatment hamsters as compared to the euglycemic
controls. Overall, it appears that hyperglycemia is amplifying the dyslipidemic affects of
a high fat/high cholesterol diet; possibly providing one reason for the associated
increased risk of CVD in diabetic individuals. Further work needs to be undertaken to
uncover the effects of altered lipid metabolism and RCT in the progression of
atherosclerosis.
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